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ABSTRACT

The present invention provides, among other things, oligonucleotide modulators of human 5'-HT2C receptor
(HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based
on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the
Exon V/Intron V junction of the human HTR2C pre-mRNA
and drive expression of HTR2C Vb splice isoform, leading
to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.
11 Claims, 14 Drawing Sheets
Specification includes a Sequence Listing.
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ANTISENSE OLIGONUCLEOTIDE
MODULATORS OF SEROTONIN RECEPTOR
2C AND USES THEREOF

tive in treating diseases like Prader-Willi Syndrome (PWS),
in which the HTR2C protein is dramatically reduced or even
absent.

CROSS REFERENCE TO RELATED
APPLICATIONS

SUMMARY

This application is a continuation application of U.S.
patent application Ser. No. 14/357,388, filed on May 9,
2014, which is a national stage application filed under 35
U.S.C. § 371, of international application serial number
PCT/US12/64319, filed Nov. 9, 2012 which claims priority
benefit under 35 U.S.C. § 119 from U.S. patent application
Ser. No. 61/707,592, filed Sep. 28, 2012 and U.S. patent
application Ser. No. 61/558,407 filed Nov. 10, 2011, all of
which are incorporated herein by reference.
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INCORPORATION-BY-REFERENCE-OF
SEQUENCE LISTING
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The
contents
of
the
file
named
"SHR1066US2_ST25.txt", which was created on Jan. 5, 2017 and
is 31 KB in size, are hereby incorporated by reference in
their entirety.
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BACKGROUND
Obesity is a serious health crisis with significant associated morbidity and mortality. It is estimated that about 64%
of Americans are overweight or obese (roughly about 97
million adults) with a general belief that the proportion of
overweight or obese people continues to rise. The prevalence of obesity worldwide is also believed to be increasing;
the World Health Organization projects 700 million adults
will be clinically obese (BMh:30, body mass index; kg/m2 )
by 2015. Co-morbidities include type 2 diabetes, hypertension, dyslipidemia, heart disease, stroke, arthritis, gallstones,
liver problems, sleep apnea and even some cancers (e.g.,
endometrial, breast, prostate, and colon cancers). Higher
body weights are also associated with increases in all-cause
mortality.
Numerous treatments for obesity have been developed
over time, although no treatment has ever gained general
acceptance. One of these treatments, fenfluramine-phentermine (commonly known as "fen-phen"), which targets
human serotonin receptor 2C (HTR2C or the 5-HT2 c receptor) protein, was very effective in achieving weight loss,
however, it was withdrawn due to side effects such as
pulmonary hypertension and heart valve damage. Eventually, it was determined that the side effects offen-phen were
due to their agonist activity at several serotonin receptors.
The 5-HT2 c receptor belongs to the family of seven
transmembrane domain receptors (7TMRs) that signal to the
internal cellular environment via heterotrimeric guanine
nucleotide-binding proteins (G proteins) in response to
stimulation by hormones, neurotransmitters and pharmacological ligands. The 5-HT2 c receptor is found primarily in
the central nervous system, and particularly in the epithelial
cells of the choroid plexus. The receptor is implicated in a
range of other diseases, ranging from obesity-linked conditions such as Prader-Willi Syndrome (PWS) and hyperphagia to psychological disorders to sleep disorders to addiction.
Existing pharmaceutical HTR2C agonists, such as fenphen and locaserin, function through directly targeting the
HTR2C protein. Such HTR2C agonists would not be effec-
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The present invention provides, among other things, oligonucleotide modulators of human 5'-HT2C receptor
(HTR2C) and improved methods and compositions for
treating HTR2C-related diseases, disorders or conditions
based on such modulators.
As described in the Examples section, the present invention is, in part, based on the discovery that short antisense
oligonucleotides that specifically target the Exon V/Intron V
junction of the human HTR2C pre-mRNA can effectively
drive the expression of the HTR2C Vb isoform by promoting Exon Vb inclusion, which in turn leads to the increased
level of the strongest serotonin receptor, the non-edited
receptor. As a result, such short antisense oligonucleotides
can enhance the serotonin receptor activity in various cells
and tissues including neurons, effecting various anti-obesity
affects. As shown in the Examples, a short 18 mer antisense
RNA oligonucleotide is surprisingly effective both in vitro
and in vivo. It induces the expression of the HTR2C Vb
isoform in the cell culture at a nanomolar concentration.
Once injected to the brain, it can be successfully delivered
to the neurons of hypothalamus and can effectively inhibit or
reduce food intake in animals. Thus, antisense oligonucleotides provided by the present invention can be used to treat
hyperphagia, obesity, and/or Prader Willi Syndrome.
In one aspect, the present invention provides an antisense
oligonucleotide of 10-50 nucleotides in length comprising a
sequence that permits specific hybridization to a target
region of a human 5'-HT2C receptor (HTR2C) pre-mRNA
under stringent conditions, wherein the target region
includes
a
nucleotide
sequence
5'
UUGGCCAUAAGAAUUGCAGCGGCUAUGCUCAAUACU 3'
(SEQ ID NO:1). In some embodiments, the stringent conditions include 50% formamide with 1 mg heparin at 42° C.
with hybridization carried out overnight and a wash in
0.2xSSC at 65° C. for 15 minutes. In some embodiments, the
sequence permits specific hybridization to nucleotides 1-18
of SEQ ID NO: 1. In some embodiments, the sequence
permits specific hybridization to nucleotides 10-27 of SEQ
ID NO: 1. In some embodiments, the sequence permits
specific hybridization to nucleotides 19-36 of SEQ ID NO: 1.
In some embodiments, the sequence permits specific hybridization to nucleotides 19-30 of SEQ ID NO: 1.
In various embodiments, the present invention provides
an antisense oligonucleotide of 10-50 nucleotides in length
comprising a sequence at least 70% identical to 10 or more
contiguous nucleotides that appear in 5' AGUAUUGAGCAUAGCCGCUGCAAUUCUUAUGGCCAA 3' (SEQ ID
NO: 15). In some embodiments, the sequence is at least 70%
identical to any of 5' UGCAAUUCUUAUGGCCAA 3'
(SEQ ID NO:8), 5' CAUAGCCGCUGCAAUUCU 3' (SEQ
ID NO:4), 5' AGUAUUGAGCAUAGCCGC 3' (SEQ ID
NO:5), or 5' GAGCAUAGCCGC 3' (SEQ ID NO:7). In
some embodiments, the sequence is selected from the group
consisting of 5' UGCAAUUCUUAUGGCCAA 3' (SEQ ID
NO:8), 5' CAUAGCCGCUGCAAUUCU 3' (SEQ ID NO4),
5' AGUAUUGAGCAUAGCCGC 3' (SEQ ID NO:5), or 5'
GAGCAUAGCCGC 3' (SEQ ID NO:7), and combination
thereof. In some embodiments, the sequence is 5'
AGUAUUGAGCAUAGCCGC 3' (SEQ ID NO:5). In some
embodiments, the sequence is 5' GAGCAUAGCCGC 3'
(SEQ ID NO:7).

US 10,415,039 B2
3

4

In various embodiments, at least one of the nucleotides in
the oligonucleotide is a chemically modified oligonucleotide. For example, in some embodiments, the chemically
modified oligonucleotide is 2'0 methyl modified. In some
embodiments, the chemically modified oligonucleotide is
thiophosphate modified. In some embodiments, the chemically modified oligonucleotide is modified to be a locked
nucleic acid.
In another aspect, the present invention provides a pharmaceutical composition including an antisense oligonucleotide of any of the embodiments described herein and a
pharmaceutically acceptable carrier.
In a further aspect, the present invention provides a
method of modulating human 5'-HT2C receptor (HTR2C)
activity in a cell including delivering an antisense oligonucleotide of any of the embodiments described herein. In
some embodiments, the cell is a neuron. In some embodiments, the neuron is in the hypothalamus region of the brain.
In some embodiments, an antisense oligonucleotide 5'
AGUAUUGAGCAUAGCCGC 3' (SEQ ID NO:5) is administered. In some embodiments, the antisense oligonucleotide
is administered at a concentration of or greater than about 5
nM (e.g., of or greater than about 10 nM, 15 nM, 20 nM, 25
nM, 30 nM, 35 nM, 40 nM, 45 nM, or 50 nM).
In various embodiments, the antisense oligonucleotide is
administered at an amount effective to increase the level of
the HTR2C Vb isoform as compared to a control level. In
some embodiments, the antisense oligonucleotide is administered at an amount effective to increase the level of the
HTR2C Vb isoform by at least about 20%, 40%, 60%, 80%,
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
or 20 fold as compared to a control level. In some embodiments, a suitable control level is the level of the HTR2C Vb
isoform in otherwise identical cells but without treatment
(e.g., the HTR2C Vb isoform level before the treatment). In
some embodiments, a suitable control level is a level indicative of the HTR2C Vb isoform expression in a patient
suffering from hyperphagia, obesity, PWS or other HTR2Crelated diseases, disorders or condition.
Among other things, the present invention provides various methods for treating diseases, disorders or conditions
associated with HTR2C dysfunction. In some embodiments,
the present invention provides a method of reducing food
consumption including administering to a subject in need of
treatment an antisense oligonucleotide described herein. In
certain embodiments, the administration of an antisense
oligonucleotide of the invention results in reduction of food
consumption by at least about 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, 90%, 95%, or more as compared to a
pre-treatment or no-treatment control.
In some embodiments, the present invention provides a
method of treating hyperphagia including administering to a
subject in need of treatment an antisense oligonucleotide
described herein.
In some embodiments, the present invention provides a
method of treating obesity including administering to a
subject in need of treatment an antisense oligonucleotide
described herein.
In some embodiments, the present invention provides a
method of treating Prader-Willi syndrome including administering to a subject in need of treatment an antisense
oligonucleotide described herein.
It will be appreciated the oligonucleotide may be delivered to the subject by any appropriate method. In some
embodiments, the antisense oligonucleotide is administered
directly to the brain of the subject.

In various embodiments, the present invention provides a
kit including an antisense oligonucleotide of any one of the
embodiments described herein and tools for administration
to the brain of a mammal.
As used in this application, the terms "about" and
"approximately" are used as equivalents. Any numerals used
in this application with or without about/approximately are
meant to cover any normal fluctuations appreciated by one
of ordinary skill in the relevant art.
Other features, objects, and advantages of the present
invention are apparent in the detailed description that follows. It should be understood, however, that the detailed
description, while indicating embodiments of the present
invention, is given by way of illustration only, not limitation.
Various changes and modifications within the scope of the
invention will become apparent to those skilled in the art
from the detailed description.
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BRIEF DESCRIPTION OF THE DRAWINGS
The drawings are for illustration purposes only, not for
limitation.
FIG. 1 illustrates regulation pathways of the serotonin 2C
receptor.
FIG. 2 illustrates exemplary sequence aligmnents of the
Exon V/Intron V junction region of the 5'-HT2C receptor
(HTR2C) from various organisms, including human (SEQ
ID NO: 17), monkey (SEQ ID NO: 18), chimpanzee (SEQ ID
NO:19), canis (SEQ ID NO:20), sus (SEQ ID NO:21),
Taurus (SEQ ID NO:22), mouse (SEQ ID NO:23) and rat
(SEQ ID NO:24).
FIG. 3 (A) illustrates the structure of an exemplary
HTR2C minigene containing the alternative Exon Vb
region. (B) illustrates the sequence of the shaded area within
the minigene diagram shown in (A), which corresponds to
the Exon V/Intron V region. The psnoRNA complementary
region is shown as framed sequence. Also depicted are the
target regions of oligos 1-9.
FIG. 4 depicts exemplary results from an RNA binding
assay with oligos 1-9.
FIG. 5 depicts exemplary results showing effects of
oligonucleotides 1-9 in modulating the expression of
HTR2C Vb vs. Va isoforms. 1 µg of each oligonucleotide
was added to HEK293 cells transfected with the reporter
gene shown in FIG. 3. Detection was by RT-PCR. The
quantification shown in the lower panel is the average of
three experiments.
FIG. 6 illustrates exemplary results showing effects of
certain shortened versions of oligo #5 in modulating the
expression of HTR2C Vb vs. Va isoforms.
FIG. 7 illustrates that oligo #5 and psnoRNA HBII-52
may target the same secondary structure of the Exon 5/Intron
5 region of HTR2C pre-mRNA. Three known splice donor
sites are shown as X. The psnoRNA complementary region
is shown as framed sequence.
FIG. 8 depicts exemplary dose-response results showing
effects on HTR2C isoform generation after treating cells
with varying concentrations of oligo #5.
FIG. 9 depicts exemplary results showing the effects on
HTR2C isoform generation after treating cells with 3' end or
5' end Cy3-modified oligo #5.
FIG. 10 illustrates exemplary results from direct sequencing of the exon inclusion band generated following treatment with oligo #5.
FIG. 11 (A) depicts a stereotactical view of a mouse
cranial injection site. (B) depicts an exemplary fluorescence
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microscopy image of the 3 rd ventrical region in a mouse
brain following injection of Cy3-labeled oligo #5.
FIG. 12 depicts exemplary results showing the total food
intake for mice over various time points following injection
with either oligo #5, control oligo or no treatment (cannulated control).
FIG. 13 illustrates exemplary results demonstrating that
oligo #5 reduces food intake in a dose dependent manner.
FIG. 14 depicts an exemplary working model for 5'-HT2C
receptor (HTR2C) Vb isoform signaling.

referred to as "patient" or "subject") being treated is an
individual (fetus, infant, child, adolescent, or adult human)
suffering from a disease.
Intrathecal administration: As used herein, the term
"intrathecal administration" or "intrathecal injection" refers
to an injection into the spinal canal (intrathecal space
surrounding the spinal cord). Various techniques may be
used including, without limitation, lateral cerebroventricular
injection through a burrhole or cisternal or lumbar puncture
or the like. In some embodiments, "intrathecal administration" or "intrathecal delivery" according to the present
invention refers to IT administration or delivery via the
lumbar area or region, i.e., lumbar IT administration or
delivery. As used herein, the term "lumbar region" or
"lumbar area" refers to the area between the third and fourth
lumbar (lower back) vertebrae and, more inclusively, the
L2-Sl region of the spine.
Membrane-penetrating peptide: As used herein, the term
"membrane-penetrating peptide" refers to any peptide that is
capable of facilitating cellular uptake of a molecule cargo
(e.g., from nano size particles to small molecules, proteins,
nucleic acids). A membrane-penetrating peptide can be
associated with a molecular cargo through chemical linkage,
covalent bonds or non-covalent interactions. Exemplary
membrane-penetrating peptides include, but are not limited
to, HIV-TAT, Antp, penetratin, polylysine, polyarginie,
VP22, Syn Bl, PTD-4, Pep-1, transportan and FGF-4 peptides. Suitable membrane-penetrating peptides can be produced using recombinant and synthetic methods or purified
from natural sources and encompass both naturally-occurring sequences and modified sequences that retain membrane penetrating ability. In many embodiments, membranepenetrating peptides are also capable of penetrating more
then one type of cell membrane. In some embodiments, the
terms "membrane-penetrating peptides" and "cell penetrating peptides" are used interchangeably.
Stability: As used herein, the term "stable" refers to the
ability of the therapeutic agent to maintain its therapeutic
efficacy (e.g., all or the majority of its intended biological
activity and/or physiochemical integrity) over extended
periods of time. The stability of a therapeutic agent, and the
capability of the pharmaceutical composition to maintain
stability of such therapeutic agent, may be assessed over
extended periods of time (e.g., for at least 1, 3, 6, 12, 18, 24,
30, 36 months or more). In general, pharmaceutical compositions described herein have been formulated such that
they are capable of stabilizing, or alternatively slowing or
preventing the degradation, of one or more therapeutic
agents formulated therewith. In the context of a formulation
a stable formulation is one in which the therapeutic agent
therein essentially retains its physical and/or chemical integrity and biological activity upon storage and during processes (such as freeze/thaw, mechanical mixing and
lyophilization). For protein stability, it can be measured by
formation of high molecular weight (HMW) aggregates, loss
of enzyme activity, generation of peptide fragments and shift
of charge profiles. For nucleotide stability, it can be measured by formation of base decomposition products, loss of
binding to a target and generation of fragments.
Stringent conditions: As used herein, the term "stringent
conditions" refers to a set of conditions for nucleic acid
hybridization that allows an oligonucleotide specifically
binds to a sequence that is complementary to the oligonucleotide. Typical exemplary stringent conditions include 50%
formamide with 1 mg heparin at 42° C. with hybridization
carried out overnight and a wash in 0.2xSSC at 65° C. for
15 minutes.
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DEFINITIONS
In order for the present invention to be more readily
understood, certain terms are first defined below. Additional
definitions for the following terms and other terms are set
forth throughout the specification.
Approximately or about: As used herein, the term
"approximately" or "about," as applied to one or more
values of interest, refers to a value that is similar to a stated
reference value. In certain embodiments, the term "approximately" or "about" refers to a range of values that fall within
25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%,
11 %, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less
in either direction (greater than or less than) of the stated
reference value unless otherwise stated or otherwise evident
from the context (except where such number would exceed
100% of a possible value).
Amelioration: As used herein, the term "amelioration" is
meant the prevention, reduction or palliation of a state, or
improvement of the state of a subject. Amelioration
includes, but does not require complete recovery or complete prevention of a disease condition.
Biologically active: As used herein, the phrase "biologically active" refers to a characteristic of any agent that has
activity in a biological system, in vitro or in vivo (e.g., in an
organism). For instance, an agent that, when administered to
an organism, has a biological effect on that organism, is
considered to be biologically active. In particular embodiments, where a protein or polypeptide is biologically active,
a portion of that protein or polypeptide that shares at least
one biological activity of the protein or polypeptide is
typically referred to as a "biologically active" portion.
Dosage form: As used herein, the terms "dosage form"
and "unit dosage form" refer to a physically discrete unit of
a therapeutic agent for the patient to be treated. Each unit
contains a predetermined quantity of active material calculated to produce the desired therapeutic effect. It will be
understood, however, that the total dosage of the composition will be decided by the attending physician within the
scope of sound medical judgment.
Improve, increase, or reduce: As used herein, the terms
"improve," "increase" or "reduce," or grammatical equivalents, indicate values that are relative to a baseline measurement, such as a measurement in the same individual prior to
initiation of the treatment described herein, or a measurement in a control individual (or multiple control individuals)
in the absence of the treatment described herein. A "control
individual" is an individual afflicted with the same form of
disease as the individual being treated, who is about the
same age as the individual being treated (to ensure that the
stages of the disease in the treated individual and the control
individual(s) are comparable).
Individual, subject, patient: As used herein, the terms
"subject," "individual" or "patient" refer to a human or a
non-human mammalian subject. The individual (also
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Subject: As used herein, the term "subject" means any
mammal, including humans. In certain embodiments of the
present invention the subject is an adult, an adolescent or an
infant. Also contemplated by the present invention are the
administration of the pharmaceutical compositions and/or
performance of the methods of treatment in-utero.
Substantial homology: The phrase "substantial homology" is used herein to refer to a comparison between amino
acid or nucleic acid sequences. As will be appreciated by
those of ordinary skill in the art, two sequences are generally
considered to be "substantially homologous" if they contain
homologous residues in corresponding positions. Homologous residues may be identical residues. Alternatively,
homologous residues may be non-identical residues will
appropriately similar structural and/or functional characteristics. For example, as is well known by those of ordinary
skill in the art, certain amino acids are typically classified as
"hydrophobic" or "hydrophilic" amino acids, and/or as
having "polar" or "non-polar" side chains Substitution of
one amino acid for another of the same type may often be
considered a "homologous" substitution.
As is well known in this art, amino acid or nucleic acid
sequences may be compared using any of a variety of
algorithms, including those available in commercial computer programs such as BLASTN for nucleotide sequences
and BLASTP, gapped BLAST, and PSI-BLAST for amino
acid sequences. Exemplary such programs are described in
Altschul, et al., Basic local aligmnent search tool, J. Mal.
Biol., 215(3): 403-410, 1990; Altschul, et al., Methods in
Enzymology; Altschul, et al., "Gapped BLAST and PSIBLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402, 1997; Baxevanis,
et al., Bioinformatics: A Practical Guide to the Analysis of
Genes and Proteins, Wiley, 1998; and Misener, et al., (eds.),
Bio informatics Methods and Protocols (Methods in Molecular Biology, Vol. 132), Humana Press, 1999. In addition to
identifying homologous sequences, the programs mentioned
above typically provide an indication of the degree of
homology. In some embodiments, two sequences are considered to be substantially homologous if at least 50%, 55%,
60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, 99% or more of their corresponding residues are homologous over a relevant stretch of
residues. In some embodiments, the relevant stretch is a
complete sequence. In some embodiments, the relevant
stretch is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60,
65, 70, 75,80,85,90,95, 100,125,150,175,200,225,250,
275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more
residues.
Substantial identity: The phrase "substantial identity" is
used herein to refer to a comparison between amino acid or
nucleic acid sequences. As will be appreciated by those of
ordinary skill in the art, two sequences are generally considered to be "substantially identical" if they contain identical residues in corresponding positions. As is well known
in this art, amino acid or nucleic acid sequences may be
compared using any of a variety of algorithms, including
those available in commercial computer programs such as
BLASTN for nucleotide sequences and BLASTP, gapped
BLAST, and PSI-BLAST for amino acid sequences. Exemplary such programs are described in Altschul, et al., Basic
local aligmnent search tool, J. Mal. Biol., 215(3): 403-410,
1990; Altschul, et al., Methods in Enzymology; Altschul et
al., Nucleic Acids Res. 25:3389-3402, 1997; Baxevanis et
al., Bioinformatics: A Practical Guide to the Analysis of
Genes and Proteins, Wiley, 1998; and Misener, et al., (eds.),
Bio informatics Methods and Protocols (Methods in Molecu-

lar Biology, Vol. 132), Humana Press, 1999. In addition to
identifying identical sequences, the programs mentioned
above typically provide an indication of the degree of
identity. In some embodiments, two sequences are considered to be substantially identical if at least 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99% or more of their corresponding
residues are identical over a relevant stretch of residues. In
some embodiments, the relevant stretch is a complete
sequence. In some embodiments, the relevant stretch is at
least 10, 15,20,25,30,35,40,45,50,55,60,65, 70, 75,80,
85,90,95, 100,125,150,175,200,225,250,275,300,325,
350, 375, 400, 425, 450, 475, 500 or more residues.
CNS delivery: As used herein, the phrase "CNS delivery"
or "injection to the brain" typically refers to an administration method that bypasses the blood brain barrier and
delivers therapeutic agents directly to the CNS or brain area.
Target tissues: As used herein, the term "target tissues"
refers to any tissue that is affected by the defects in or lower
than desired activity from the 5-HT2 c receptor, especially
the central nervous system. In some embodiments, target
tissues include those tissues in which there is an abnormality
in the editing of the RNA for the 5-HT2 c receptor. In some
embodiments, target tissues include those tissues that display disease-associated pathology, symptom, or feature. As
used herein, a target tissue may be a brain target tissue, a
spinal cord target tissue an/or a peripheral target tissue.
Exemplary target tissues are described in detail below.
Therapeutically effective amount: As used herein, the
term "therapeutically effective amount" refers to an amount
of a therapeutic agent which confers a therapeutic effect on
the treated subject, at a reasonable benefit/risk ratio applicable to any medical treatment. The therapeutic effect may
be objective (i.e., measurable by some test or marker) or
subjective (i.e., subject gives an indication of or feels an
effect). In particular, the "therapeutically effective amount"
refers to an amount of a therapeutic agent or composition
effective to treat, ameliorate, or prevent a desired disease or
condition, or to exhibit a detectable therapeutic or preventative effect, such as by ameliorating symptoms associated
with the disease, preventing or delaying the onset of the
disease, and/or also lessening the severity or frequency of
symptoms of the disease. A therapeutically effective amount
is commonly administered in a dosing regimen that may
comprise multiple unit doses. For any particular therapeutic
agent, a therapeutically effective amount (and/or an appropriate unit dose within an effective dosing regimen) may
vary, for example, depending on route of administration, on
combination with other pharmaceutical agents. Also, the
specific therapeutically effective amount (and/or unit dose)
for any particular patient may depend upon a variety of
factors including the disorder being treated and the severity
of the disorder; the activity of the specific pharmaceutical
agent employed; the specific composition employed; the
age, body weight, general health, sex and diet of the patient;
the time of administration, route of administration, and/or
rate of excretion or metabolism of the specific agent
employed; the duration of the treatment; and like factors as
is well known in the medical arts.
Treatment: As used herein, the term "treatment" (also
"treat" or "treating") refers to any administration of a
therapeutic agent (e.g., oligonucleotide) that partially or
completely alleviates, ameliorates, relieves, inhibits, delays
onset of, reduces severity of and/or reduces incidence of one
or more symptoms or features of a particular disease,
disorder, and/ or condition (e.g., hyperphagia, obesity, Prader
Willi Syndrome). Such treatment may be of a subject who
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does not exhibit signs of the relevant disease, disorder and/or
condition and/or of a subject who exhibits only early signs
of the disease, disorder, and/or condition. Alternatively or
additionally, such treatment may be of a subject who exhibits one or more established signs of the relevant disease,
disorder and/or condition.

non-edited receptor prevents the obesity and hyperphagia
associated with the loss of the HTR2C in transgenic mouse
model, suggesting that the non-edited receptor is the major
anti-obesity form of the HTR2C. A diagram illustrating
regulation of the serotonin receptor through alternative
splicing and RNA editing is shown in FIG. 1.
An alternative splicing region covering the human
HTR2C Exon5/Intron5 boundary is shown below (uppercase: Exon5, lowercase: Intron5).

5

DETAILED DESCRIPTION
The present invention provides, among other things,
improved compositions and methods for modulating human
5'-HT2C receptor (HTR2C) activity and for treatment of a
disease, disorder or condition associated with HTR2C. In
particular, the present invention is based on antisense oligonucleotide modulators of HTR2C that enhance the
HTR2C activity by promoting Exon Vb inclusion, resulting
in increased expression of the HTR2C Vb isoform, which in
turn leads to the increased level of the strong serotonin
receptor, the non-edited receptor. In some embodiments, the
present invention provides antisense oligonucleotides that
specifically target the Exon V/Intron V junction of a human
5'-HT2C receptor (HTR2C) pre-mRNA. In this application,
the terms "exon 5", "exon V", "Exon 5" and "Exon V" are
used inter-changeably, and the terms "intron 5", "intron V",
"Intron 5" and "Intron V" are also used inter-changeably.
Various aspects of the invention are described in detail in
the following sections. The use of sections is not meant to
limit the invention. Each section can apply to any aspect of
the invention. In this application, the use of "or" means
"and/or" unless stated otherwise.
Human Serotonin Receptor 2C (HTR2C) and Related Diseases and Conditions
The HTR2C belongs to the family of seven transmembrane domain receptors (7TMRs) that signal to the internal
cellular environment via heterotrimeric guanine nucleotidebinding proteins (G proteins) in response to stimulation by
hormones, neurotransmitters and pharmacological ligands.
The HTR2C significantly regulates mood, anxiety, feeding,
and reproductive behavior. The HTR2C is found primarily in
the central nervous system, and particularly in the epithelial
cells of the choroid plexus. The receptor is implicated in a
range of other diseases, ranging from obesity-linked conditions such as Prader-Willi Syndrome (PWS) and hyperphagia to psychological disorders to sleep disorders to addiction. In particular, it was reported that the 5-HT2 c receptor
may underlie the insatiable appetite in Prader-Willi syndrome.
The activity of the HTR2c is partly regulated by RNA
editing. It has been reported that there existed different
isoforms ofHTR2C with altered G protein-coupling efficacy
generated by RNA editing, which converts genomically
encoded adenosine residues into inosines. See, Wang Q., et
al. "Altered G Protein-Coupling Functions of RNA Editing
Isoform and Splicing Variant Serotonin2 c Receptors," J.
Neurochem., 74, 1290-1300 (2000), the teachings of which
are hereby incorporated by reference.
In particular, two alternative splicing donor sites exist in
Exon V, which gives rise to Exon Va and Exon Vb. Exon Vb
skipping generates the HTR2C Va splice isoform, which
results in a truncated and non-functional protein. Exon Vb
inclusion results in the HTR2C Vb splice isoform, which
may give rise to edited receptor and non-edited receptor as
a result of RNA editing mechanism. The edited version
demonstrates weak serotonin response while the non-edited
version has strong serotonin response. Expression of the

10
(SEQ ID NO,

2)

ATTATGTCTGGCCACTACCTAGATATTTGTGCCCCGTCTGGATTTCTTTA
GATGTTTTATTTTCAACAGCGTCCATCATGCACCTCTGCGCTATATCGCT
15

GGATCG*GTATGTAGCAATACGTAATCCTATTGAGCATAGCCGTTTCAAT
TCGCGGACTAAGGCCATCATGAAGATTGCTATTGTTTGGGCAATTTCTAT
AG*gtaaataaaactttttggccataagaattgcagcggctatgctcaat
20

actttcggattatgtactgtgaacaacgtacagacgtcgactggtaa
*indicate SA and SB splice donor sites.
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Modulators of HTR2C
As discussed in the Examples below, the present inventors
have successfully identified antisense oligonucleotide
modulators that change the splicing of the HTR2C. In
particular, those modulators enhance or promote Exon Vb
inclusion resulting in increased non-edited version of the
HTR2C.
Antisense Oligonucleotides
Among other things, the present invention provides antisense oligonucleotides useful for modulation ofHTR2C. An
antisense oligonucleotide suitable for the present invention
includes any oligonucleotide that is capable of modulating
HTR2C or that can rescue or ameliorate one or more
diseases, disorders or conditions associated with HTR2C.
In some embodiments, provided antisense oligonucleotides are capable of hybridizing or binding to a target
region ofHTR2C pre-mRNA such that it changes splicing of
the HTR2C. In some embodiments, provided antisense
oligonucleotides are capable of hybridizing or binding to a
target region of HTR2C pre-mRNA such that it enhances or
promotes Exon Vb inclusion resulting in the HTR2C splice
isoform Vb.
It will be appreciated that hybridization of an antisense
oligonucleotide to a target region of HTR2C pre-mRNA
may be performed in vitro or in vivo. Hybridization may be
performed under low, medium, and/or stringent hybridization conditions, as is well known in the art. In general,
stringent hybridization conditions refer to standard hybridization conditions under which nucleic acid molecules,
including oligonucleotides, are used to identify molecules
having complementary nucleic acid sequences. Stringent
hybridization conditions typically permit binding between
nucleic acid molecules having at least about 50%, 55%,
60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more
nucleic acid sequence identity. Standard conditions are disclosed, for example, in Sambrook et al., 1989, Molecular
Cloning: A Laboratory Manual, Cold Spring Harbor Labs
Press, the contents of which is incorporated herein by
reference in its entirety. Formulae to calculate the appropriate hybridization and wash conditions to achieve hybridization permitting 50%, 40%, 30%, 20%, 10%, 5% or less
mismatch of nucleotides are available in the art, for
example, in Meinkoth et al., 1984, Anal. Biochem. 138,
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267-284; the contents of which is incorporated herein by
reference in its entirety. It will be appreciated that hybrids
between oligonucleotides (14-20 bp) and immobilized DNA
show decreased stability and should be taken into account
when defining optimal conditions for their hybridization.
Hybridization condition stringency can be affected by
buffer ionic strength, base composition of the nucleotide, the
length of the shortest chain in the duplex (n), and the
concentration of helix destabilizing agents such as formamide. For example, hybridization stringency can be altered
by adjusting the salt and/or formamide concentrations and/or
by changing the temperature. The stringency can be adjusted
either during the hybridization step, or in post hybridization
washes. An example of stringent hybridization conditions
for hybridization of complementary nucleic acids which
have more than 100 complementary residues on a filter in a
Southern or Northern blot is 50% formamide with 1 mg of
heparin at 42° C., with the hybridization being carried out
overnight. An example of stringent wash conditions is a
0.2xSSC wash at 65° C. for 15 minutes. In some embodiments, a high stringency wash is preceded by a low stringency wash to remove back-ground probe signal. An
example medium stringency wash for a duplex of, e.g., more
than 100 nucleotides, is l00xSSC at 45° C. for 15 minutes.
An example low stringency wash for a duplex of, e.g., more
than 100 nucleotides, is 4xSSC at 40° C. for 15 minutes. In
general, a signal to noise ratio of 2x (or higher) than that
observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.
In some embodiments, provided oligonucleotides bind to
a target region of HTR2C including a nucleotide sequence
found at the exon5-intron5 boundary. Sequences of the
human and mouse HTR2C exon5/intron5 sequence are
shown in Table 1 (uppercase: exon5, lowercase: intron5).

nucleotides bind to nucleotides 1-18 of SEQ ID NO: 1. In
some embodiments, provided oligonucleotides bind to
nucleotides 10-27 of SEQ ID NO: 1. In some embodiments,
provided oligonucleotides bind to nucleotides 19-36 of SEQ
ID NO: 1. In some embodiments, provided oligonucleotides
bind to nucleotides 19-30 of SEQ ID NO:1.
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TABLE 1
HTR2C Exon5/Intron5 sequence
human HTR2c
exon5/intron5

mouse HTR2c
exon5/intron5

ATTATGTCTGGCCACTACCTAGATATTT SEQ ID
GTGCCCCGTCTGGATTTCTTTAGATGTT NO, 2
TTATTTTCAACAGCGTCCATCATGCACC
TCTGCGCTATATCGCTGGATCGGTATGT
AGCAATACGTAATCCTATTGAGCATAGC
CGTTTCAATTCGCGGACTAAGGCCATCA
TGAAGATTGCTATTGTTTGGGCAATTTC
TATAGgtaaataaaActttttggccata
agaaTtgcagcggctatgctcaatactt
tcggattatgtactgtgaacaacgtaca
gacgtcgactggtaa
ATTATGTCTGGCCTTTACCTAGATATTT SEQ ID
GTGCCCCGTCTGGATTTCACTAGATGTG NO, 3
CTATTTTCAACTGCGTCCATCATGCACC
TCTGCGCCATATCGCTGGACCGGTATGT
AGCAATACGTAATCCTATTGAGCATAGC
CGGTTCAATTCGCGGACTAAGGCCATCA
TGAAGATTGCCATCGTTTGGGCAATATC
AATAGgtaattatacctggccatagaat
TgcaGcggctatgctcaataccttcgga
ttatgtactgtgaacaacctacagacgt
cgactggtaa

In some embodiments, provided oligonucleotides bind to
the exon5-intron5 boundary regions shown above (SEQ ID
NO:2 or SEQ ID NO:3). In some embodiments, provided
oligonucleotides bind to the intron regions shown in Table 1.
In some embodiments, provided oligonucleotides bind to a
target region including a nucleotide sequence 5' UUGGCCAUAAGAAUUGCAGCGGCUAUGCUCAAUACU 3'
(SEQ ID NO:1). In some embodiments, provided oligo-
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Provided oligonucleotides may bind to a target region of
a serotonin receptor 2C from a different species. Thus, in
some embodiments, provided oligonucleotides bind to a
target region that is substantially homologous to SEQ ID
NO:1. For example, provided oligonucleotides may bind to
a target region that has a sequence at least 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID
NO:1.
In some embodiments, provided oligonucleotides bind to
a target region that is substantially identical to SEQ ID
NO:1. For example, provided oligonucleotides bind to a
target region that has a sequence at least 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99% or more identical to SEQ ID
NO:1.
In some embodiments, provided oligonucleotides bind to
a target region that is substantially homologous to SEQ ID
NO:2. In some embodiments, a suitable HTR2C target
region includes a nucleotide sequence that has a sequence at
least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more
homologous to SEQ ID NO:2.
In some embodiments, provided oligonucleotides bind to
a target region that is substantially identical to SEQ ID
NO:2. For example, provided oligonucleotides bind to a
target region that has a sequence at least 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99% or more identical to SEQ ID
NO:2.
In some embodiments, provided oligonucleotides bind to
a target region that is substantially homologous to SEQ ID
NO:3. For example, provided oligonucleotides bind to a
target region that has a sequence at least 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID
NO:3.
In some embodiments, provided oligonucleotides bind to
a target region that is substantially identical to SEQ ID
NO:3. For example, provided oligonucleotides bind to a
target region that has a sequence at least 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99% or more identical to SEQ ID
NO:3.
In various embodiments, the present invention provides
an antisense oligonucleotide of 10-50 nucleotides in length
comprising a sequence at least 70% (e.g., 75%, 80%, 85%,
90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or
more) identical to 10 or more contiguous nucleotides that
appear in 5' AGUAUUGAGCAUAGCCGCUGCAAUUCUUAUGGCCAA 3' (SEQ ID NO:9), which is a complementary sequence of a target region defined by SEQ ID
NO:1.
Exemplary short antisense oligonucleotides suitable for
the present invention are listed in Table 2:
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TABLE 2
Short Antisense RNA Oligonucleotides
Oligo #

Sequence ( 5' -3')

SEQ ID NO,
5

2

CAUAGCCGCUGCAAUUCU

4

5

AGUAUUGAGCAUAGCCGC

5

5-5

AGUAUUGAGCAU

6

5-3

GAGCAUAGCCGC

7

5-10

GCAUAGCCGC

10

6

UGCAAUUCUUAUGGCCAA

16
8

15

In some embodiments, an antisense oligonucleotide in
accordance with the present invention has a sequence that is
at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, 98%, or 99% identical to any of SEQ ID NO: 4, SEQ
ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO: 8, and
SEQ ID NO:16. In some embodiments, the sequence is
selected from SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6,
SEQ ID NO:7, SEQ ID NO: 8, SEQ ID NO:16, and
combinations thereof. In some embodiments, the sequence is
SEQ ID NO:7. In some embodiments, the sequence is SEQ
ID NO:5.
It will be appreciated that an antisense oligonucleotide in
accordance with the present invention may be of any appropriate length. For example, in some embodiments, an antisense oligonucleotide is 10-50 nucleotides in length. In
some embodiments, an antisense oligonucleotide is 10-30
nucleotides in length. In certain embodiments, an antisense
oligonucleotide is 15-40 nucleotides in length. In some
embodiments, an antisense oligonucleotide is 10, 11, 12, 13,
14, 15, 16, 17, 1~ 1~ 20,22,2~ 26,28,30,3Z 34,36,38,
40, 42, 44, 46, 48, or 50 nucleotides in length
"Percent (%) nucleic acid sequence identity" with respect
to the nucleotide sequences identified herein is defined as the
percentage of nucleotides in a candidate sequence that are
identical with the nucleotides in the reference sequence,
after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.
Alignment for purposes of determining percent nucleic acid
sequence identity can be achieved in various ways that are
within the skill in the art, for instance, using publicly
available computer software such as BLAST, ALIGN or
Megalign (DNASTAR) software. Those skilled in the art can
determine appropriate parameters for measuring alignment,
including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
Preferably, the WU-BLAST-2 software is used to determine
amino acid sequence identity (Altschul et al., Methods in
Enzymology, 266, 460-480 (1996); http://blast.wustl/edu/
blast/README.html). WU-BLAST-2 uses several search
parameters, most of which are set to the default values. The
adjustable parameters are set with the following values:
overlap span=!, overlap fraction=0.125, world threshold
(T)=ll. HSP score (S) and HSP S2 parameters are dynamic
values and are established by the program itself, depending
upon the composition of the particular sequence, however,
the minimum values may be adjusted and are set as indicated
above.
Chemical Modifications
RNA molecules, including the antisense oligonucleotides
described herein, may be chemically modified to change
(e.g., increase or decrease) intracellular stability and half-
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life. Possible modifications include the addition of flanking
sequences at the 5' and/or 3' ends of the molecule or the use
of phosphorothioate (also known as thiophosphate) linkages
rather than phosphodiesterase linkages within the backbone
of the molecule. In addition, one or more ribose groups may
be modified to add a methyl moiety to the 2'-OH to form a
2'-methoxy moiety (referred to as 2'O-methyl-modified).
Also, the 2'-OH moiety can be linked to the or 3' or 4'-carbon
of ribose by a methylene or ethylene linker, typically a
methylene linker to the 4'-carbon, to form a "locked nucleic
acid" (see WO 98/39352 and WO 99/14226, the contents of
which are incorporated herein by reference).
In certain embodiments, chemical modification also
includes the use of nontraditional bases such as inosine,
queosine, and wybutosine, as well as acetyl-, methyl-, thio-,
and other similarly modified forms of adenine, cytidine,
guanine, thymine, and uridine, which are not as easily
recognized by endogenous endonucleases. Examples of
modified bases include uridine and/or cytidine modified at
the 5-position, e.g., 5-(2-amino )propyl uridine, 5-bromo
uridine; adenosine and/or guanosines modified at the 8
position, e.g., 8-bromo guanosine; deaza nucleotides, e.g.,
7-deaza-adenosine; and 0- and N-alkylated nucleotides,
e.g., N6-methyl adenosine.
In certain embodiments, the sugar moiety can be modified, typically at the 2'-OH of ribose. Examples of such
modifications include instances where the 2' OH-group is
replaced by a group selected from H, OR, R, halo, SH, SR,
NH 2 , NHR, NR2 or ON, where R is C 1 -C 6 alkyl, alkenyl or
alkynyl and halo is F, Cl, Br or I.
Further, chemical modification can encompass modified
backbones such as morpholino and/or further non-natural
internucleoside linkages such as siloxane, sulfide, sulfoxide,
sulfone, sulfonate, sulfonamide, and sulfamate; formacetyl
and thioformacetyl; alkene-containing; methyleneimino and
methylenehydrazino; amide, and the like.
One or more nucleotides (or linkages) within the
sequences described herein can be modified. For example, a
20-mer oligonucleotide may contain 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 modified
nucleotides. In certain embodiments, a modified oligonucleotide will contain as few modified nucleotides as are necessary to achieve a desired level of in vivo stability and/or
bioaccessibility while maintaining cost effectiveness.
Therapeutic Uses
Antisense oligonucleotide modulators of HTR2C
described herein may be used to treat various HTR2c related
diseases, disorders and conditions.
Treatment of Prader-Willi Syndrome
Prader-Willi Syndrome (PWS) is a genetic disorder, with
a gene missing on chromosome 15, which is characterized
by hyperphagia. People with this condition are typically
obese, have reduced muscle tone and mental ability, and
have sex glands that produce little or no hormones.
Newborns with PWS typically have several of the following symptoms: are small for gestational age; have genitals that are not well developed (in boys, the testicles cannot
be felt in the scrotum); have problems sucking and swallowing, and often do not gain weight; have poor muscle tone
(hypotonia); often have a weak cry; delayed motor development; and show changes in the face, such as "almondshaped" eyes and a small, downtumed mouth.
Affected children, beginning at about age 1 to 4, generally
develop an intense craving for food, leading to weight gain
and morbid obesity. These children also tend to have shorter
stature and below-normal IQ. In later childhood and in
adulthood, the symptoms of PWS may include: incomplete
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sexual development (hypogonadism, infertility); low muscle
mass; short stature; scoliosis; sleep disorders (disruptions of
the normal sleep cycle, sleep apnea); compulsive-like
behaviors; abnormal glucose tolerance; above normal level
of the hormone insulin in the blood; failure to respond to
luteinizing hormone releasing factor, high carbon dioxide
levels; lack of oxygen supply; right-sided heart failure; and
knee and hip problems.
Antisense oligonucleotide modulators of HTR2C
described herein may be used to treat the PWS syndrome.
The terms, "treat" or "treatment," as used herein, refers to
amelioration of one or more symptoms associated with the
disease, prevention or delay of the onset of one or more
symptoms of the disease, and/or lessening of the severity or
frequency of one or more symptoms of the disease.
In some embodiments, treatment refers to partially or
completely alleviation, amelioration, relief, inhibition,
delaying onset, reducing severity and/or incidence of one or
more symptoms in an PWS patient, including, but not
limited to, hyperphagia, below-normal IQ, low muscle mass;
short stature; scoliosis; sleep disorders (disruptions of the
normal sleep cycle, sleep apnea); compulsive-like behaviors; abnormal glucose tolerance; above normal level of the
hormone insulin in the blood; failure to respond to luteinizing hormone releasing factor; high carbon dioxide levels;
lack of oxygen supply; right-sided heart failure; and knee
and hip problems.
In some embodiments, treatment refers to reduced food
intake or consumption in a subject in need of treatment. In
certain embodiments, the amount of food intake or consumption may be reduced by at least about 10%, 20%, 30%,
40%, 50%, 60%, 70%, 80%, 90%, 95%, or more as compared to a pre-treatment or no-treatment control (e.g., the
amount of food intake or consumption by the same subject
pre-treatment or the amount of food intake or consumption
by a control subject with similar diseased or developmental
stage but without treatment).
In some embodiments, treatment refers to improved body
weight loss (e.g., total weight loss, percent body weight loss
per week, per month, per two months, per six months, etc.).
In certain embodiments, total body weight loss is, on average, about 0.1 kg, about 0.2 kg, about 0.3 kg, about 0.4 kg,
about 0.5 kg, about 0.6 kg, about 0.7 kg, about 0.8 kg, about
0.9 kg, about 1 kg, about 1.1 kg, about 1.2 kg, about 1.3 kg,
about 1.4 kg, about 1.5 kg, about 1.6 kg, about 1.7 kg, about
1.8 kg, about 1.9 kg, about 2 kg, about 2.1 kg, about 2.2 kg,
about 2.3 kg, about 2.4 kg, about 2.5 kg, about 2.6 kg, about
2.7 kg, about 2.8 kg, about 2.9 kg, about 3 kg, or more, per
week. In some embodiments, percent body weight loss is a
decrease by, on average, about 5%, about 10%, about 15%,
about 20%, about 25%, about 30%, about 35%, about 40%,
about 45%, about 50%, about 55%, about 60%, about 65%,
about 70%, about 75%, about 80%, about 85%, about 90%,
about 95%, about 100%, or more per week. As used herein,
percent body weight loss is determined by comparing the
total body weight loss to the base total body weight before
the loss.
In some embodiments, treatment refers to reduced or
prevented weight gain (e.g., total weight gain, percent body
weight gain per week, per month, per two months, per six
months, etc.). In some embodiments, total body weight gain
is, on average, less than about 0.1 kg, about 0.2 kg, about 0.3
kg, about 0.4 kg, about 0.5 kg, about 0.6 kg, about 0.7 kg,
about 0.8 kg, about 0.9 kg, about 1 kg, about 1.1 kg, about
1.2 kg, about 1.3 kg, about 1.4 kg, about 1.5 kg, about 1.6
kg, about 1.7 kg, about 1.8 kg, about 1.9 kg, about 2 kg,
about 2.1 kg, about 2.2 kg, about 2.3 kg, about 2.4 kg, about

2.5 kg, about 2.6 kg, about 2.7 kg, about 2.8 kg, about 2.9
kg, or about 3 kg, per week. In some embodiments, percent
body gain is, on average, less than about 0.1 %, about 0.5%,
about 1%, about 1.5%, about 2%, about 2.5%, about 3%,
about 3.5%, about 4%, about 5%, about 10%, about 15%,
about 20%, or about 25%, per week. As used herein, percent
body weight gain is determined by comparing the total body
weight gain to the base total body weight before the gain.
In other embodiments, treatment refers to increased survival (e.g., survival time). For example, treatment can result
in an increased life expectancy of a patient. In some embodiments, treatment according to the present invention results
in an increased life expectancy of a patient by more than
about 5%, about 10%, about 15%, about 20%, about 25%,
about 30%, about 35%, about 40%, about 45%, about 50%,
about 55%, about 60%, about 65%, about 70%, about 75%,
about 80%, about 85%, about 90%, about 95%, about 100%,
about 105%, about 110%, about 115%, about 120%, about
125%, about 130%, about 135%, about 140%, about 145%,
about 150%, about 155%, about 160%, about 165%, about
170%, about 175%, about 180%, about 185%, about 190%,
about 195%, about 200% or more, as compared to the
average life expectancy of one or more control individuals
with Prader-Willi Syndrome without treatment. In some
embodiments, treatment according to the present invention
results in an increased life expectancy of a patient by more
than about 1 month, about 2 months, about 3 months, about
4 months, about 5 months, about 6 months, about 7 months,
about 8 months, about 9 months, about 10 months, about 11
months, about 12 months, about 2 years, about 3 years, about
4 years, about 5 years, about 6 years, about 7 years, about 8
years, about 9 years, about 10 years or more, as compared
to the average life expectancy of one or more control
individuals with similar disease form without treatment. In
some embodiments, treatment according to the present
invention results in long term survival of a patient. As used
herein, the term "long term survival" refers to a survival
time or an increased life expectancy of longer than about 10
years, 15 years, 20 years, 25 years, 30 years or longer.
Treatment of Other HTR2C-Associated Diseases
Inventive methods and compositions of the present invention are particularly useful for treating those diseases having
a 5'-HT2C receptor (HTR2C) etiology, component or relationship. Giuseppe's 5-HT2C Receptors in the Pathophysiology of CNS Disease, 1st Edition, G. Di Giovamii et. al.
(Humana Press, 2010; incorporated herein by reference)
discloses various diseases associated, caused and/or affected
by HTR2C dysregulation. Representative diseases having an
HTR2C etiology or component include, for example and
without limitation, metabolic disorders such as obesity,
hyperphagia, lack of satiety, and diabetes; psychiatric disorders such as schizophrenia (Sodhi, M, S. et. al., RNA
editing of the 5-HT(2C) receptor is reduced in schizophrenia, Molecular Psychiatry, 2001; (6): 373-9; incorporated
herein by reference), depression (Iwamoto, K, et. al., Estimating RNA editing efficiency of five editing sites in the
serotonin 2C receptor by pyrosequencing, RNA, 2005; (11 ):
1596-1603; incorporated herein by reference), suicidal tendencies (Niswender, C, M., et. al., RNA editing ofthe human
serotonin 5-HT2C receptor: alterations in suicide and implications for erotonergic pharmacotherapy, Neuropsychopharmacology, 2001; (24 ): 478-91, incorporated herein by
reference) and bipolar disorder; epilepsy including sensitivity to seizure and a reduced seizure threshold; addictive
disorders (e.g., cocaine addiction, tetrahydrocamiabinol
addiction, nicotine addition); and sleep disorders (insonmia,
abnormal REM sleep). Several of the listed methods involve
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delivery of one of the compos1t10ns described herein to
neurons, such as those located in the brain.
Metabolic Disorders
A first group of conditions treated according to the present
invention are metabolic disorders. Such metabolic disorders
can be caused by insufficient metabolism of calorie intake
(e.g., obesity), elevated blood glucose (e.g., diabetes) or an
inability to control appetite (e.g., hyperphagia).
Obese individuals or individuals suffering from obesity
are generally individuals having a body mass index (BMI) of
at least 25 or greater or at least 30 or greater. Obesity may
or may not be associated with insulin resistance. Obesity can
lead to other conditions such as type 2 diabetes, hypertension, dyslipidemia, heart disease, stroke, arthritis, gallstones,
liver problems, sleep apnea and some cancers (e.g., endometrial, breast, prostate, and colon cancers).
Diabetes refers to high blood sugar or ketoacidosis, as
well as chronic, general metabolic abnormalities arising
from a prolonged high blood sugar status or a decrease in
glucose tolerance. Diabetes encompasses both the type I and
type II (Non Insulin Dependent Diabetes Mellitus or
NIDDM) forms of the disease. Subjects with type II diabetes
often suffer from insulin resistance, which refers to a state in
which a normal amount of insulin produces a subnormal
biologic response relative to the biological response in a
subject that does not have insulin resistance. An insulin
resistance disorder generally refers to any disease or condition that is caused by or contributed to by insulin resistance.
Hyperphagia, also known as polyphagia, refers to excessive hunger and/or an excessive impulse to eat.
Psychiatric Disorders
Psychiatric disorders that can be treated using the compositions and methods described herein include, but are not
limited to, psychosis, schizophrenia, anxiety (Hackler, E, A.,
et. al., 5-HT(2C) receptor RNA editing in the amygdala of
C57BL/6J, DBA/2J, and BALB/cJ mice, Neurosci Res, 2006;
(55): 96-104; incorporated herein by reference) (including
generalized anxiety disorder, panic disorder, social phobia,
obsessive compulsive disorder, and post-traumatic stress
disorder (PTSD)), suicidal tendencies and mood disorders
(including depression, mania, bipolar disorders). In certain
embodiments, one or more of schizophrenia, depression,
suicidal tendencies and bipolar disorder are treated.
Epilepsy
Epilepsy and associated conditions represent another
group of disorders that can be treated using the compositions
and methods described herein. Epilepsy is a common
chronic neurological disorder that is characterized by recurrent unprovoked seizures. These seizures may be transient
signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain. Illustrative examples
of epileptic seizures treatable with the methods and compositions described herein include tonic-clonic, clonic (with or
without tonic features), absence (typical or atypical), myoclonic absence, tonic, myoclonic, massive bilateral myoclonus, negative myoclonus, eyelid myclonia (accompanied or
not by absence seizures), myoclonic-atonic, atonic, reflex,
focal sensory (with elementary sensory symptoms, such as
occipital and parietal lobe seizures, or experiential sensory
symptoms, such as temporo parieto occipital junction seizures, and the like), focal motor (with elementary clonic
motor signs, with asymmetrical tonic motor signs or seizure,
such as supplementary motor seizures, with typical automatisms, also referred to as temporal lobe automatisms, such as
mesial temporal lobe seizures, with hyperkinetic automatisms, with focal negative myoclonus, and the like), inhibitory motor, gelastic, hemiclonic, secondarily generalized,

reflex seizures in focal epilepsy syndromes, generalized
tonic-clonic status epilepticus, clonic status epilepticus,
absence status epilepticus, tonic status epilepticus, myoclonic status epilepticus, epilepsia partialis continua, aura continua, limbic status epilepticus, hemiconvulsive status epilepticus. Methods of the invention include reducing the
likelihood of epilepsy and reducing the severity of a seizure.
Addictive Disorders
Another group of disorders that can be treated using the
compositions and methods described herein are addictive
disorders, particularly those disorders where serotonin plays
a role in maintaining the addictive behavior. Typically,
addiction is classified as a behavioral disorder, characterized
by a compulsive search for the product that causes this
dependency, despite the harmful consequences on the health,
family, professional life, etc. of which the dependent person
is fully aware. Examples of addictions treatable by the
methods described herein include cocaine addiction, tetrahydrocamiabinol addiction, opioid addiction and nicotine
addition. Treatment can be assessed, for example, by reduction in cravings, reduction in use of a substance, reduction
of relapse of addiction.
Sleep Disorders
The present invention also provides compos1t10ns and
methods that treat sleep disorders. Sleep disorders include
an inability to fall asleep or stay asleep, collectively known
as insomnia. Insomnia can be transient or chronic. Sleep
disorders also include conditions where the quality of sleep
is disturbed, such as when a subject has abnormal REM
sleep.
Autonomic Dysregulation
The present invention also provides compos1t10ns and
methods that treat disease associated with dysregulation of
one or more physiological functions controlled by the autonomic nervous system. Autonomic dysregulation (Dysautonomia) includes an inability to maintain homeostasis and
regulate a response to basic changes such as temperature,
walking, sitting, sleeping, eating, desiring, digesting food or
thirst. Autonomic dysregulation also includes conditions
related to thermal regulation, in which the subject resides is
a state of hypo- and/or hyperthermia. Data suggests that
modulation of HTR2C, such as with a HTR2C agonist, can
play an important role in controlling thermal regulation
(Deecher, Darlene, C., et. al., Alleviation of Thermoregulatory Dysfunction with the New Serotonin and Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in
Ovarlectomized Rodent Models, Neuroendocrinology, 2007;
(3): 1376; and Findlay, J. D., et. al, The mechanism of body
temperature changes induced by intraventicular injections
of adrenaline, noradrenaline and 5-hydroxytryptamine in
the ox (bas Taurus), The journal of Physiology, 1967; (189):
329-336; both of which are incorporated herein by reference.)
Pharmaceutical Compositions
The present invention further provides pharmaceutical
compositions comprising therapeutic actives in accordance
with the invention (e.g., antisense oligonucleotides),
together with one or more pharmaceutically acceptable
excipients. Such pharmaceutical compositions may optionally comprise one or more additional therapeutically-active
substances.
Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for ethical administration to humans, it will be understood by the skilled artisan
that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceu-
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tical compositions suitable for administration to humans in
order to render the compositions suitable for administration
to various animals is well understood, and the ordinarily
skilled veterinary pharmacologist can design and/or perform
such modification with merely ordinary, if any, experimentation.
Formulations of the pharmaceutical compos1t10ns
described herein may be prepared by any method known or
hereafter developed in the art of pharmacology. In general,
such preparatory methods include the step of bringing the
active ingredient into association with a diluent or another
excipient and/or one or more other accessory ingredients,
and then, if necessary and/or desirable, shaping and/or
packaging the product into a desired single- or multi-dose
unit.
A pharmaceutical composition in accordance with the
invention may be prepared, packaged, and/or sold in bulk, as
a single unit dose, and/or as a plurality of single unit doses.
As used herein, a "unit dose" is discrete amount of the
pharmaceutical composition comprising a predetermined
amount of the active ingredient. The amount of the active
ingredient is generally equal to the dosage of the active
ingredient which would be administered to a subject and/or
a convenient fraction of such a dosage such as, for example,
one-half or one-third of such a dosage.
Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition in accordance with
the invention will vary, depending upon the identity, size,
and/or condition of the subject treated and further depending
upon the route by which the composition is to be administered. By way of example, the composition may comprise
between 0.1 % and 100% (w/w) active ingredient.
Pharmaceutical formulations may additionally comprise a
pharmaceutically acceptable excipient, which, as used
herein, includes any and all solvents, dispersion media,
diluents, or other liquid vehicles, dispersion or suspension
aids, surface active agents, isotonic agents, thickening or
emulsifying agents, preservatives, solid binders, lubricants
and the like, as suited to the particular dosage form desired.
Remington's The Science and Practice of Pharmacy, 21 st
Edition, A. R. Gennaro (Lippincott, Williams & Wilkins,
Baltimore, Md., 2006; incorporated herein by reference)
discloses various excipients used in formulating pharmaceutical compositions and known techniques for the preparation
thereof. Except insofar as any conventional excipient
medium is incompatible with a substance or its derivatives,
such as by producing any undesirable biological effect or
otherwise interacting in a deleterious manner with any other
component(s) of the pharmaceutical composition, its use is
contemplated to be within the scope of this invention.
In some embodiments, a pharmaceutically acceptable
excipient is at least 95%, at least 96%, at least 97%, at least
98%, at least 99%, or 100% pure. In some embodiments, an
excipient is approved for use in humans and for veterinary
use. In some embodiments, an excipient is approved by
United States Food and Drug Administration. In some
embodiments, an excipient is pharmaceutical grade. In some
embodiments, an excipient meets the standards of the United
States Pharmacopoeia (USP), the European Pharmacopoeia
(EP), the British Pharmacopoeia, and/or the International
Pharmacopoeia.
Pharmaceutically acceptable excipients used in the manufacture of pharmaceutical compositions include, but are not
limited to, inert diluents, dispersing and/or granulating
agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents,

lubricating agents, and/or oils. Such excipients may optionally be included in pharmaceutical formulations. Excipients
such as cocoa butter and suppository waxes, coloring agents,
coating agents, sweetening, flavoring, and/or perfuming
agents can be present in the composition, according to the
judgment of the formulator.
General considerations in the formulation and/or manufacture of pharmaceutical agents may be found, for example,
in Remington: The Science and Practice of Pharmacy 21 st
ed., Lippincott Williams & Wilkins, 2005 (incorporated
herein by reference).
In some embodiments, liposomes may be used to deliver
antisense oligonucleotides described herein. As used herein,
a liposome is an artificially-prepared vesicle composed of a
lipid bilayer. Liposomes can be prepared by disrupting
biological membranes (such as by sonication). Liposomes
may include natural phospholipids, or mixed lipid chains
with surfactant properties (e.g., egg phosphatidylethanolamine). A liposome design may employ surface ligands
for targeting desired target tissues.
Administration
The present invention provides methods of administering
an effective amount of a therapeutic active described herein
(e.g., an antisense oligonucleotide) to a subject in need of
treatment.
Antisense oligonucleotides described herein may be
administered through various administration routes including, but not limited to, intravenous, subcutaneous, intramuscular, parenteral, transdermal, or transmucosal (e.g., oral or
nasal). In some embodiments, antisense oligonucleotides
described herein are directly delivered to the central nervous
system (i.e., brain) of a subject in need of treatment.
CNS Delivery
Typically, direct CNS delivery or injection to the brain
bypasses the blood brain barrier and delivers therapeutic
agents directly to the brain tissues. Suitable CNS delivery
techniques and routes include, but are not limited to, intraparenchymal, intracerebral, intravetricular cerebral (ICY),
intrathecal (e.g., IT-Lumbar, IT-cistema magna) administrations and any other techniques and routes for injection
directly or indirectly to the CNS and/or CSF.
In some embodiments, intrathecal delivery may be used
according to the present invention. As used herein, intrathecal administration (also referred to as intrathecal injection)
refers to an injection into the spinal canal (intrathecal space
surrounding the spinal cord). Various techniques may be
used including, without limitation, lateral cerebroventricular
injection through a burrhole or cisternal or lumbar puncture
or the like. Exemplary methods are described in Lazorthes
et al. Advances in Drug Delivery Systems and Applications
in Neurosurgery, 143-192 and Omaya et al., Cancer Drug
Delivery, 1: 169-179, the contents of which are incorporated
herein by reference.
Typically, a therapeutic composition may be injected at
any region surrounding the spinal canal. In some embodiments, a therapeutic composition is injected into the lumbar
area or the cisterna magna or intraventricularly into a
cerebral ventricle space. As used herein, the term "lumbar
region" or "lumbar area" refers to the area between the third
and fourth lumbar (lower back) vertebrae and, more inclusively, the L2-Sl region of the spine. Typically, intrathecal
injection via the lumbar region or lumber area is also
referred to as "lumbar IT delivery" or "lumbar IT administration." The term "cisterna magna" refers to the space
around and below the cerebellum via the opening between
the skull and the top of the spine. Typically, intrathecal
injection via cisterna magna is also referred to as "cisterna
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magna delivery." The term "cerebral ventricle" refers to the
cavities in the brain that are continuous with the central
canal of the spinal cord. Typically, injections via the cerebral
ventricle cavities are referred to as intravetricular Cerebral
(ICY) delivery.
In some embodiments, intrathecal administration may be
performed by either lumbar puncture (i.e., slow bolus) or via
a port-catheter delivery system (i.e., infusion or bolus). In
some embodiments, the catheter is inserted between the
laminae of the lumbar vertebrae and the tip is threaded up
the thecal space to the desired level.
Blood Brain Barrier-Crossing Moieties
In some embodiments, antisense RNA oligonucleotides
described herein may be modified to facilitate crossing the
blood brain barrier (BBB) and/or cellular uptake into neurons. For example, antisense RNA oligonucleotides
described herein may be associated with a BBB-crossing
moiety. In some embodiments, a suitable BBB-crossing
moiety binds to a receptor on the surface of brain cells,
thereby inducing, e.g., receptor-mediated endocytosis.
Exemplary BBB-crossing moieties include, but are not
limited to, hormones (e.g., thyroids, steroids) and peptides
(e.g., IGF-I, IGF-II, insulin, or transferrin). In some embodiments, antisense RNA oligonucleotides described herein are
associated with a cell- or membrane-penetrating peptide to
facilitate uptake into brain cells, such as neurons. Without
wishing to be bound by theory, it is contemplated that cellor membrane-penetrating peptides are particularly useful in
facilitating cellular uptake of antisense RNA oligonucleotides into arcuate nucleus neurons, for example, proopiomelanocortin (POMC) positive neurons of the hypothalamus, which display a leaky BBB.
Exemplary cell- or membrane-penetrating peptides
include, but are not limited to, HIV-TAT, Antp, penetratin,
polylysine, polyarginie, VP22, Syn Bl, PTD-4, Pep-1, transportan and FGF-4 peptides. See e.g., Langel, U. (ed.),
"Cell-Penetrating Peptides: Processes and Applications",
CRC Press, Boca Raton, Fla., 2002; Arzumanov, Abes, R.,
et. al., Arginine-rich cell penetrating peptides: Design,
structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides, 2008, J Pept Sci; (14):
455-60; Said, Hassane, F., Cell penetrating peptides: overview and applications to the delivery of oligonucleotides,
2010, Cell Mo! Life Sci; (67):715-26 for further discussion
and all of which are incorporated herein by reference.
Suitable cell- or membrane-penetrating peptides encompass
both naturally-occurring peptides and modified peptides that
retain membrane penetrating ability and can be produced
using recombinant and synthetic methods or purified from
natural sources.
A BBB-crossing moiety including a cell- or membranepenetrating peptide may be attached at the 5' end or 3' end
of the oligo. It will be appreciated that a BBB-crossing
moiety including a cell- or membrane-penetrating peptide
may be associated with an antisense RNA oligo in any
·
·
( e.g., a ce ]] manner. For example, a BBB-crossmg
m01ety
or membrane-penetrating peptide) may be chemically conjugated, or fused to an antisense RNA oligo directly or
indirectly via a peptide linker or spacer. In some embodiments, a BBB-crossing moiety (e.g., a cell- or membranepenetrating peptide) may be associated with an antisense
RNA oligo via non-covalent interactions.
Inventive methods of the present invention contemplate
single as well as multiple administrations of a therapeutically effective amount of antisense oligonucleotides
described herein. Antisense oligonucleotides can be administered at regular intervals, depending on the nature, severity

and extent of the subject's condition. In some embodiments,
a therapeutically effective amount of an antisense oligonucleotide of the present invention may be administered
periodically at regular intervals (e.g., once every year, once
every six months, once every five months, once every three
months, bimonthly (once every two months), monthly (once
every month), biweekly (once every two weeks), weekly,
twice a week, three times a week, daily, or twice a day).
As described above, the term "therapeutically effective
amount" is largely determined based on the total amount of
the therapeutic agent contained in the pharmaceutical compositions of the present invention. A therapeutically effective
amount is commonly administered in a dosing regimen that
may comprise multiple unit doses. For any particular composition, a therapeutically effective amount (and/or an
appropriate unit dose within an effective dosing regimen)
may vary, for example, depending on the desired therapeutic
effects, route of administration or on combination with other
pharmaceutical agents. Also, the specific therapeutically
effective amount (and/or unit dose) for any particular patient
may depend upon a variety of factors including the disorder
being treated and the severity of the disorder; the activity of
the specific pharmaceutical agent employed; the specific
composition employed; the age, body weight, general
health, sex and diet of the patient; the time of administration,
route of administration; the duration of the treatment; and
like factors as is well known in the medical arts.
In some embodiments, a therapeutically effective dose
may range from about 0.005 mg/kg weight to 500 mg/kg
weight, e.g., from about 0.005 mg/kg weight to 400 mg/kg
weight, from about 0.005 mg/kg weight to 300 mg/kg
weight, from about 0.005 mg/kg weight to 200 mg/kg
weight, from about 0.005 mg/kg weight to 100 mg/kg
weight, from about 0.005 mg/kg weight to 90 mg/kg weight,
from about 0.005 mg/kg weight to 80 mg/kg weight, from
about 0.005 mg/kg weight to 70 mg/kg weight, from about
0.005 mg/kg weight to 60 mg/kg weight, from about 0.005
mg/kg weight to 50 mg/kg weight, from about 0.005 mg/kg
weight to 40 mg/kg weight, from about 0.005 mg/kg weight
to 30 mg/kg weight, from about 0.005 mg/kg weight to 25
mg/kg weight, from about 0.005 mg/kg weight to 20 mg/kg
weight, from about 0.005 mg/kg weight to 15 mg/kg weight,
from about 0.005 mg/kg weight to 10 mg/kg weight.
In some embodiments, the therapeutically effective dose
may also be defined by mg/kg brain weight. As one skilled
in the art would appreciate, the brain weights and body
weights can be correlated. Dekaban AS. "Changes in brain
weights during the span of human life: relation of brain
weights to body heights and body weights," Ann Neural
1978; 4:345-56. Thus, in some embodiments, the dosages
can be converted as shown in Table 3.
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Dosage conversion
Correlation between Brain Weights, body weights and ages of males
-~==~~="'-'"'-"""'--'"-"'-"'-"''-'-"""'-''--"-=""'-='-"'""'--"=--=""'--Age (year)

Brain weight (kg)

Body weight (kg)

3 (31-43 months)
4-5

1.27
1.30

15.55
19.46

In some embodiments, the therapeutically effective dose
may also be defined by mg/15 cc of cerebrospinal fluid
(CSF). As one skilled in the art would appreciate, therapeutically effective doses based on brain weights and body
weights can be converted to mg/15 cc ofCSF. For example,
the volume of CSF in adult humans is approximately 150
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mL (Johanson CE, et al. "Multiplicity of cerebrospinal fluid
functions: New challenges in health and disease," Cerebraspinal Fluid Res. 2008 May 14; 5:10). Therefore, single dose
injections of 0.1 mg to 50 mg protein to adults would be
approximately 0.01 mg/15 cc ofCSF (0.1 mg) to 5.0 mg/15
cc of CSF (50 mg) doses in adults.
It is to be further understood that for any particular
subject, specific dosage regimens should be adjusted over
time according to the individual in need and the professional
judgment of the person administering or supervising the
administration of the therapeutic agent and that dosage
ranges set forth herein are exemplary only and are not
intended to limit the scope or practice of the claimed
invention.
Gene Therapy
In some embodiments, antisense oligonucleotides may be
delivered as naked recombinant RNAs in pharmaceutical
compositions through conventional administration routes
described above. In some embodiments, constructs encoding
an antisense oligonucleotide of interest may be delivered
through gene therapy approaches. Various gene therapy
vectors may be used to practice the present invention.
In some embodiments, retroviral vectors are used for
expressing an antisense oligonucleotide of interest. The
retroviruses are a group of single-stranded RNA viruses
characterized by an ability to convert their RNA to doublestranded DNA in infected cells by a process of reversetranscription (Coffin, 1990). The resulting DNA then stably
integrates into cellular chromosomes as a provirus and
directs synthesis of viral proteins. The integration results in
the retention of the viral gene sequences in the recipient cell
and its descendants. The retroviral genome contains three
genes, gag, pol, and env that code for capsid proteins,
polymerase enzyme, and envelope components, respectively. A sequence found upstream from the gag gene
contains a signal for packaging of the genome into virions.
Two long terminal repeat (LTR) sequences are present at the
5' and 3' ends of the viral genome. These contain strong
promoter and enhancer sequences and are typically also
required for integration in the host cell genome (Coffin,
1990).
In order to construct a retroviral vector, a nucleic acid
encoding a gene of interest is inserted into the viral genome
in the place of certain viral sequences to produce a virus that
is replication-defective. In some embodiments, in order to
produce virions, a packaging cell line containing the gag,
pol, and env genes but without the LTR and packaging
components is constructed (Marni et al., 1983). When a
recombinant plasmid containing a cDNA, together with the
retroviral LTR and packaging sequences is introduced into
this cell line (by calcium phosphate precipitation for
example), the packaging sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral
particles, which are then secreted into the culture media
(Nicolas and Rubenstein, 1988; Temin, 1986; Mann et al.,
1983 ). The media containing the recombinant retroviruses is
then collected, optionally concentrated, and used for gene
transfer. Retroviral vectors are able to infect a broad variety
of cell types. Suitable retroviral based vectors include, but
are not limited to, lentivirus based vectors including various
pseuodotyped lentiviral vectors. Exemplary lentiviral vectors are described in U.S. Pat. Nos. 5,834,256 and 5,716,832,
the teachings of which are hereby incorporated by reference.
Other viral vectors may be employed as expression constructs in the present invention. Vectors derived from viruses
such as vaccinia virus (Ridgeway, 1988; Baichwal and
Sugden, 1986; Coupar et al., 1988) adeno-associated virus

(AAV) (Ridgeway, 1988; Baichwal and Sugden, 1986; Hermonat and Muzycska, 1984) and herpesviruses may be
employed. In some embodiments, adenovirus-, or adenoassociated virus based vectors (Levrero et al., 1991; GomezFaix et al., 1992; Stratford-Perricaudet and Perricaudet,
1991; Stratford-Perricaudet et al., 1990; Rich et al., 1993)
are used. Various recombinant AAV vectors (e.g., AAVl,
AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, or AAV8) are
available in the art and may be used to practice the invention.
Various methods may be used to deliver viral vectors
encoding a gene of interest and are known in the art. For
example, recombinant adeno- or adeno-associated virus
based vectors may be delivered through trachea instillation
(Rosenfeld et al., 1991; Rosenfeld et al., 1992), muscle
injection (Ragot et al., 1993), peripheral intravenous injections (Herz and Gerard, 1993), stereotactic inoculation into
the brain (Le Gal La Salle et al., 1993), and intrathecal
delivery as described herein.
Kits
The present invention further provides kits or other
articles of manufacture which contains a therapeutic agent of
the present invention (e.g., antisense oligonucleotides ), tools
for administration, and/or instructions for its use. For
example, kits or other articles of manufacture may include
a container, an IDDD, a catheter and any other articles,
devices or equipment useful in intrathecal administration
and associated surgery. Suitable containers include, for
example, bottles, vials, syringes (e.g., pre-filled syringes),
ampules, cartridges, reservoirs, or lyo-jects. The container
may be formed from a variety of materials such as glass or
plastic. In some embodiments, a container is a pre-filled
syringe. Suitable pre-filled syringes include, but are not
limited to, borosilicate glass syringes with baked silicone
coating, borosilicate glass syringes with sprayed silicone, or
plastic resin syringes without silicone.
Typically, the container holds formulations containing a
therapeutic agent of the invention (e.g., antisense oligonucleotides) and a label on, or associated with, the container
that may indicate directions for reconstitution and/or use.
For example, the label may indicate that the formulation is
reconstituted to concentrations as described above. The label
may further indicate that the formulation is useful or
intended for, for example, IT administration. In some
embodiments, a container may contain a single dose of a
stable formulation containing a therapeutic agent. In various
embodiments, a single dose of the stable formulation is
present in a volume of less than about 15 ml, 10 ml, 5.0 ml,
4.0 ml, 3.5 ml, 3.0 ml, 2.5 ml, 2.0 ml, 1.5 ml, 1.0 ml, or 0.5
ml. Alternatively, a container holding the formulation may
be a multi-use vial, which allows for repeat administrations
(e.g., from 2-6 administrations) of the formulation. Kits or
other articles of manufacture may further include a second
container comprising a suitable diluent (e.g., BWFI, saline,
buffered saline). Upon mixing of the diluent and the formulation, the final concentration of a therapeutic moiety in the
reconstituted formulation will generally be at least 1 mg/ml
(e.g., at least 5 mg/ml, at least 10 mg/ml, at least 25 mg/ml,
at least 50 mg/ml, at least 75 mg/ml, at least 100 mg/ml).
Kits or other articles of manufacture may further include
other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles,
IDDDs, catheters, syringes, and package inserts with
instructions for use.
The invention will be more fully understood by reference
to the following examples. They should not, however, be
construed as limiting the scope of the invention. All literature citations are incorporated by reference.
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EXAMPLES

complementary region (framed sequence in FIG. 3B). The
minigene was constructed as described previously (0. Stoss
et. al., Brain Research Protocols; (4), 383; 1999). Briefly,
the minigene was constructed using 3'-end sequence regions
of exon V (approximately 100 nt in length) and the 5' end of
intron V (approximately 97 nucleotides in length) from the
human serotonin receptor 2C gene. The sequences were
amplified from HEK293 genomic DNA via PCR amplification, ligated and subcloned into the pCRII vector (Invitrogen®) under the control of a SP6 promoter sequence. Each
of the various short antisense RNA oligonucleotides tested
in the oligo walk experiments are shown in FIG. 3B, along
with their corresponding binding sites on the HTR2C premRNA sequence. All of the short anti sense RNA oligonucleotides were synthesized as 2'-O-methyl thioates, to enhance
stability against exogenous nucleases and facilitate direct
uptake by the cell. The short antisense RNA oligonucleotides tested include those listed in Table 5.

Example 1: Identification of Oligonucleotides that
Target the HTR2C Exon V/Intron V Region by
Oligo Walk
As described above, the 5-HT2 c receptor (HTR2C) plays
an important role in the control of appetite and energy
balance. It has been previously demonstrated that HTR2Cknockout mice develop hyperphagia and obesity. It was also
reported that mice with altered HTR2C RNA editing display
characteristics of Prader-Willi Syndrome (PWS). HTR2C
transcripts generally undergo extensive processing in the
region spanning the competing alternative splicing donor
sites of exon5. HTR2C pre-mRNA forms an extensive
base-paired structure that is subject to RNA editing and
regulation by snoRNAs, such as psnoRNA MBII-52, which
is missing in patients with PWS. It has been demonstrated
that psnoRNA MBII-52 plays an important role in generating the non-edited HTR2C Vb isoform, which is the most
active form of the 5-HT2 c receptor, and it acts through
inducing a change in alternative splicing. Kishore S. Science, (2006), 311:230-232.
This example illustrates identification of oligonucleotides
that may substitute the loss of psnoRNA in PWS patients.
Specifically, oligo-walking experiments were performed
using short antisense RNA oligonucleotides complementary
to various regions of the exon V/intron V junction of the
HTR2C encompassing the psnoRNA binding region, to
identify potential sites for altering HTR2C pre-mRNA splicing (FIG. 1). Sequences of the human and mouse HTR2C
exon V/intron V sequence are shown in Table 4 (uppercase:
exon V, lowercase: intron V). Comparison of the exon
V/intron V sequence between several different organisms are
shown in FIG. 2 and demonstrates a high degree of homology across different species in this region.

5

10

15

20

TABLE 5
Short Antisense RNA Oligonucleotides

25

Oligo #

human HTR2c
exonV /
intronV

ATTATGTCTGGCCACTACCTAGATATTTGT SEQ ID
GCCCCGTCTGGATTTCTTTAGATGTTTTAT NO, 2
TTTCAACAGCGTCCATCATGCACCTCTGCG
CTATATCGCTGGATCGGTATGTAGCAATAC
GTAATCCTATTGAGCATAGCCGTTTCAATT
CGCGGACTAAGGCCATCATGAAGATTGCTA
TTGTTTGGGCAATTTCTATAGgtaaataaa
ActttttggccataagaaTtgcagcggcta
tgctcaatactttcggattatgtactgtga
acaacgtacagacgtCgactggtaa

35

40

ATTATGTCTGGCCTTTACCTAGATATTTGT SEQ ID
GCCCCGTCTGGATTTCACTAGATGTGCTAT NO, 3
TTTCAACTGCGTCCATCATGCACCTCTGCG
CCATATCGCTGGACCGGTATGTAGCAATAC
GTAATCCTATTGAGCATAGCCGGTTCAATT
CGCGGACTAAGGCCATCATGAAGATTGCCA
TCGTTTGGGCAATATCAATAGgtaattata
cctggccatagaatTgCaGcggctatgctc
aataccttcggattatgtactgtgaacaac
ctacagacgtcgactGgtaa

Panel A of FIG. 3 depicts the structure of the human
HTR2C reporter mini gene (minigene) used for the oligo
walk experiment. The minigene encompasses exon V which
contains the alternative exon Vb region. The shaded area
within the minigene diagram corresponds to the sequence
shown in panel B. Several important elements are located
within the exon V/intron V region, such as the snoRNA

1

UAAUCCGAAAGUAUUGAG

1

2

CAUAGCCGCUGCAAUUCU

4

3

UAGCAAUCUUCAUGAUGG

10

4

UUAGUCCGCGAAUUGAAA

11

5

AGUAUUGAGCAUAGCCGC

5

5-5

AGUAUUGAGCAU

6

5-3

GAGCAUAGCCGC

7

6

UGCAAUUCUUAUGGCCAA

8

7

AUGCUCAAUAGGAUUACG

12

8

AGAAAUUGCCCAAACAAU

13

9

AAAGUUUUAUUUACCUAU

14

45

50
mouse HTR2c
exonV/
intronV

SEQ ID NO,

30

TABLE 4
HTR2C exon5/intron5 sequence

Sequence (5' -3')

55

60

In vitro RNA structure assays were performed to confirm
binding for each of the tested antisense oligonucleotides, to
the target region within the minigene pre-mRNA structure.
For the study, each antisense RNA oligonucleotide was
independently mixed with minigene pre-mRNA, hybridized
under stringent conditions and digested with RNase A/Tl.
Binding of the antisense RNA oligonucleotide to the minigene results in a change in pre-mRNA three dimensions
structure and its overall sensitivity to RNase cleavage.
Following treatment, RNA was recovered and analyzed on
a denaturing polyacrylamide gel. FIG. 4 shows exemplary
results indicating that each of anti sense RNA oligos 1-9 bind
to the HTR2C pre-mRNA minigene (FIG. 4).
Example 2: Oligo 5 and Other Oligonucleotides
Promote Exon Vb Inclusion

65

This example demonstrates that certain short antisense
RNA oligonucleotides that bind to specific regions within
the exon V/intron V junction of pre-mRNA sequence can
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alter splicing and promote exon Vb inclusion, resulting in
generation of the HTR2C Vb isoform.
For each experiment, HEK293 cells were transiently
co-transfected, using a calcium phosphate precipitation
method, with the HTR2C minigene plasmid, an antisense
RNA oligo and a GFP expression vector (to visually monitor
the rate of transfection). Specifically, HEK cells were cultured in DMEM containing 10% (v/v) fetal bovine serum
(Invitrogen). RNA oligonucleotides and plasmid DNAs
were transfected into cells with calcium phosphate. Typically, 50 ng of RNA nucleotide and 100 ng of DNA plasmid
were transfected into lxl0 6 cells. Serotonin receptor 2C
gene splicing analysis was performed as described in
Kishore S. Science, (2006), 311:230-232. Briefly, total RNA
was isolated 17-24 hours post transfection, subjected to
RT-PCR using each antisense RNA oligonucleotide as a
primer and the reaction product analyzed on a 2% agarose
TBE gel (FIG. 5). The data show that antisense RNA
oligonucleotides including oligo #5, and to a lesser extent
oligo #2, and oligo #6, promoted exon Vb inclusion and led
to generation of the HTR2C Vb splice isoform according to
predicted band size (FIG. 5).
As shown in FIG. 5, oligo #5 had the strongest effect on
splice site selection promoting exon Vb inclusion. Further
experiments were performed using shortened versions of
oligo #5, such as oligos #5-3 (GAGCAUAGCCGC), #5-5
(AGUAUUGAGCAU), and #5-10 (GCAUAGCCGC), to
examine if smaller regions within the foot print of oligo #5
could be used to elicit the similar effect as the full length 18
mer. Exemplary results are shown in FIGS. 5 and 6. As can
be seen, these shortened oligonucleotides showed a smaller
effect on exon inclusion than the full-length oligo #5.
As shown in FIG. 3, the oligos #2, #5 and #6 all bind to
intron V region that forms a stem structure with exon Vb.
Evolutionary, this region is highly conserved, showing only
one U38>G substitution in mouse and rat that will interfere
with the stem, but a total of three C35>U and G129>A
substitutions in naked mole and microbat that keep the stem
structure. For example, the binding site of oligo #5 overlaps
with about half of the psnoRNA binding site (framed
sequence in FIG. 3) located on the complementary RNA
strand of exon Vb. Without wishing to be bound by theory,
it is contemplated that both the psonRNA and oligo #5 target
the same secondary structure on the HTR2C (FIG. 7).

Since psnoRNA promotes exon Vb inclusion through
RNA editing which involves enzymatic modification, we
determined if oligo #5 acts similarly through directly modulating editing. To that end, we directly sequenced the exon
inclusion band caused by oligo #5 and, as shown in FIG. 10,
we did not observe evidence for editing, suggesting that
oligo #5 acts directly on the RNA, without inducing an
enzymatic modification.
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This example demonstrates that oligo 5, once injected to
the brain, can be successfully delivered to the neurons of
hypothalamus.
We injected 2 µg Cy3-labeled oligo#5 stereotactically into
the third ventricle of naive BL6 mice. Specifically, 9-12
week old adult male naive C57BL/6 mice were stereotaxically implanted with a guide cannula to the coordinates of
0.83 mm posterior to the bregma, 4.0 mm below the surface
of the skull, and 0.0 mm lateral to midline. The cannula tip
was located above the 3rd ventricle. After the surgery, the
mice were individually housed and deprived of food with
continuous water supply. The injection was performed 24
hours after cannula implant. An injector with 1.0 mm
projection (Plastics One) was inserted through the guide
cannula and used to inject 2 ul of RNA nucleotides during
at least 2 minutes. Food was resumed after the injection. The
body mass and food intake were recorded at the designated
time points. No seizures were detected in any of the mice,
following injection of oligo #5.
Approximately 18 hours after injection, each mouse was
sacrificed, and the brain tissue was harvested for analysis. As
shown in FIG. 12, 18 hours post injection, fluorescence was
detected in the nuclei of the arcuate nucleus, which consists
mainly of neurons, including preopiomelanocortin positive
neurons expressing the 5-HTR2C (FIG. 11). These results
demonstrate that oligo #5 are successfully delivered to the
nucleus of the neurons in the hypothalamus following injection to the brain.
Example 5. Oligo #5 Reduces Food Intake in Mice

45

Example 3. Oligo #5 is Effective in the Nanomolar
Range
Oligo #5 is selected as an exemplary oligonucleotide of
the present invention for further studies. In this example, we
used the full length oligo #5 to determine its efficacy in cell
culture and demonstrated that oligo #5 works in the nanomolar range.
Specifically, oligo #5 and a reporter minigene were transfected into HEK293 cells as described above. Oligo #5 was
added without transfection reagent to the cells that take up
phosphor-thio RNAs. As shown in FIG. 8, the oligo starts
showing an effect in driving the expression of the 5-HTR2C
Vb isoform at 5 nM and the effect is strongest in the 40 nM
range.
To follow the oligonucleotide in cells, we labeled either
the 5' or 3' end with Cy3. All oligos are taken up by the cell
and accumulate in the nucleus, as expected. As shown in
FIG. 10, the 5' modification does not affect the effectiveness
of oligo #5. However, in this particular experiment, the 3'
end modification with Cy3 reduces its effectiveness (FIG. 9).
Cy3 is attached to the last base of the oligo.

Example 4: Oligo 5 is Successfully Delivered to
Neurons of Hypothalamus In Vivo
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As described in Examples 2 and 3, in vitro, oligo #5
increased the abundance of the non-edited version of the
HTR2C. Therefore, oligo #5 acts like a genetic agonist for
the serotonin receptor 2C. In this example, we further
demonstrated that oligo #5 causes an anorexic response in
vive by measuring the food intake after oligo #5 injection.
As described above, 9-12 week old adult male naive
C57BL/6 mice were stereotaxically implanted with a guide
cannula to the coordinates of 0.83 mm posterior to the
bregma, 4.0 mm below the surface of the skull, and 0.0 mm
lateral to midline. The mice were randomly divided into
three study groups, individually housed, deprived of food
and given a continuous supply of water. Approximately 24
hours post surgery, an injector with a 1.0 mm projection was
inserted through the guide cannula and used to inject 4 µl of
either oligo #5 or control oligo against human SMN2 at 1
nmol (-8 µg). The third group was injected nothing (cannulated control). Food was resumed immediately following
the injection. Total body mass (data not shown) and food
intake was recorded at various time points. As shown in FIG.
12, mice injected with oligo #5 showed a significant reduction in food intake for at least eight hours post the injection
compared to both the control oligo and cannulated control
mice.
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We then tested if oligo #5 acts in a dose dependent
manner. 9-12 week old adult male naive C57BL/6 mice were
cannulated, divided up into four study groups and maintained as described above. Approximately 24 hours post
surgery, the mice received either no injection, control oligo,
0.1 µg of oligo #5, or 2.5 µg of oligo #5. Food was resumed
immediately following the injection. Total body mass (data
not shown) and food intake was recorded at various time
points over a 2 day period. As shown in FIG. 13, oligo #5
reduces food intake in a dose dependent manner. However,
even the lower dose, 0.1 µg (20 pmol) of oligo #5, shows an
effect in reduction of food intake by mice.
Taken together, injection of oligo #5 to the brain effectively inhibits or reduces animal food consumption, indicating that oligo #5, and other similar oligonucleotides, can be
used to treat hyperphagia in PWS patients.

hyperphagia and other related symptoms in PWS and other
diseases, disorders or conditions.
EQUIVALENTS
5

10

15

Example 6. Exemplary Model
As described above, our data demonstrate that small
antisense RNA oligonucleotides 1-9 are able to bind to
different regions within the HTR2C pre-mRNA structure,
and some are capable of inducing changes in its three
dimensional conformation. Our data also suggest small
antisense oligo #5, which overlaps with approximately half
of the snoRNA binding site located on the complementary
RNA strand in exon Vb (FIG. 7), is able to promote exon Vb
inclusion in vitro to produce the HTR2C Vb isoform (FIG.
5). In vivo experiments demonstrate that injection of oligo
#5 into the brain is directly taken up into the cell and
dramatically reduces food intake by mice. Furthermore,
injection of oligo #5 is able to promote an anorexic state in
a dependent response.
Previous studies have demonstrated that activation of the
regulated splice site within this region of the 5-HTR2C
pre-mRNA needs to be activated to generate the 5-HTR2C
Vb isoform, which is the most active form of the receptor
(Kishore et. al., Science, (311), 230; 2005). In humans, this
is physiologically achieved through binding of psnoRNAs to
the snoRNA-CR to alter the pre-mRNA secondary structure.
This is supported by the findings that patients diagnosed
with PWS, fail to produce psnoRNAs or the resulting active
Vb isoform; leading to a state of chronic hyperphagia. This
suggests that both the psnoRNA and oligo #5 may target the
same secondary structure on the HTR2C pre-mRNA to
produce the active Vb isoform (FIG. 14).
Based on these data, and without wishing to be bound by
any particular theory, we propose that small antisense RNA
oligonucleotides, for example, oligo #5, can be used as a
genetic agonist to promote generation of the active HTR2C
Vb active isoform. As illustrated in FIG. 14, activation of the
HTR2C receptor in POMC positive neurons quickly
increases the transcription factor c-fos that turns on POMC
in the arcuate nucleus. Once active, the POMC peptide is
enzymatically processed into several small peptides such as
alpha, beta and gamma melanocyte stimulating hormone
(MSH). MSH peptides tum on the MC3/4R receptors in the
paraventricular nucleus, which generate an anorexic signal.
The same receptors inhibit the activity in the LHA (lateral
hypothalamus), which blocks anorexic signal. As a result,
the mice stop eating. Conversely, a subject who predominantly expresses the weakly active Vb or inactive Va isoform, such as in the case of a PWS patient, fails to generate
sufficient c-fos activation to leave a chronic state of hyperphagia. Without wishing to be bound by any particular
theory, it is contemplated that injection of oligo #5 activates
c-fos, which triggers this "natural" cascade, thereby treating
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Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments of the invention
described herein. The scope of the present invention is not
intended to be limited to the above Description, but rather is
as set forth in the appended claims. The articles "a", "an",
and "the" as used herein in the specification and in the
claims, unless clearly indicated to the contrary, should be
understood to include the plural referents. Claims or descriptions that include "or" between one or more members of a
group are considered satisfied if one, more than one, or all
of the group members are present in, employed in, or
otherwise relevant to a given product or process unless
indicated to the contrary or otherwise evident from the
context. The invention includes embodiments in which
exactly one member of the group is present in, employed in,
or otherwise relevant to a given product or process. The
invention also includes embodiments in which more than
one, or all of the group members are present in, employed in,
or otherwise relevant to a given product or process. Furthermore, it is to be understood that the invention encompasses
variations, combinations, and permutations in which one or
more limitations, elements, clauses, descriptive terms, etc.,
from one or more of the claims is introduced into another
claim dependent on the same base claim (or, as relevant, any
other claim) unless otherwise indicated or unless it would be
evident to one of ordinary skill in the art that a contradiction
or inconsistency would arise. Where elements are presented
as lists, e.g., in Markush group or similar format, it is to be
understood that each subgroup of the elements is also
disclosed, and any element(s) can be removed from the
group. It should it be understood that, in general, where the
invention, or aspects of the invention, is/are referred to as
comprising particular elements, features, etc., certain
embodiments of the invention or aspects of the invention
consist, or consist essentially of, such elements, features,
etc. For purposes of simplicity those embodiments have not
in every case been specifically set forth herein. It should also
be understood that any embodiment of the invention, e.g.,
any embodiment found within the prior art, can be explicitly
excluded from the claims, regardless of whether the specific
exclusion is recited in the specification.
It should also be understood that, unless clearly indicated
to the contrary, in any methods claimed herein that include
more than one act, the order of the acts of the method is not
necessarily limited to the order in which the acts of the
method are recited, but the invention includes embodiments
in which the order is so limited. Furthermore, where the
claims recite a composition, the invention encompasses
methods of using the composition and methods of making
the composition. Where the claims recite a composition, it
should be understood that the invention encompasses methods of using the composition and methods of making the
composition.
INCORPORATION OF REFERENCES
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All publications and patent documents cited in this application are incorporated by reference in their entirety to the
same extent as if the contents of each individual publication
or patent document were incorporated herein.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>

28

SEQ ID NO 1
LENGTH, 36
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE,

1

uuggccauaa gaauugcagc ggcuaugcuc aauacu

<210>
<211>
<212>
<213>

36

SEQ ID NO 2
LENGTH, 295
TYPE, DNA
ORGANISM, Homo sapiens

<400> SEQUENCE,

2

attatgtctg gee act acct agatatttgt gccccgtctg gatttcttta gatgttttat

60

tttcaacagc gtccatcatg cacctctgcg ctatatcgct ggatcggtat gtagcaatac

120

gtaatcctat tgagcatagc cgtttcaatt cgcggactaa ggccatcatg aagattgcta

180

ttgtttgggc aatttctata ggtaaataaa actttttggc cataagaatt gcagcggcta

240

tgctcaatac tttcggatta tgtactgtga acaacgtaca gacgtcgact ggtaa

295

<210>
<211>
<212>
<213>

SEQ ID NO 3
LENGTH, 290
TYPE, DNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 3

attatgtctg gcctttacct agatatttgt gccccgtctg gatttcacta gatgtgctat

60

tttcaactgc gtccatcatg cacctctgcg ccatatcgct ggaccggtat gtagcaatac

120

gtaatcctat tgagcatagc cggttcaatt cgcggactaa ggccatcatg aagattgcca

180

tcgtttgggc aatatcaata ggtaattata cctggccata gaattgcagc ggctatgctc

240

aataccttcg gattatgtac tgtgaacaac ctacagacgt cgactggtaa

290

<210>
<211>
<212>
<213>

SEQ ID NO 4
LENGTH, 18
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 4
cauagccgcu gcaauucu

<210>
<211>
<212>
<213>

18

SEQ ID NO 5
LENGTH, 18
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 5
aguauugagc auagccgc

<210>
<211>
<212>
<213>

18

SEQ ID NO 6
LENGTH, 12
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 6
aguauugagc au

12
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-continued
<210>
<211>
<212>
<213>

SEQ ID NO 7
LENGTH, 12
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 7
gagcauagcc gc

<210>
<211>
<212>
<213>

12

SEQ ID NO 8
LENGTH, 18
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 8
ugcaauucuu auggccaa

<210>
<211>
<212>
<213>

18

SEQ ID NO 9
LENGTH, 36
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 9
aguauugagc auagccgcug caauucuuau ggccaa

<210>
<211>
<212>
<213>

36

SEQ ID NO 10
LENGTH, 18
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 10
uagcaaucuu caugaugg

<210>
<211>
<212>
<213>

18

SEQ ID NO 11
LENGTH, 18
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 11
uuaguccgcg aauugaaa

<210>
<211>
<212>
<213>

18

SEQ ID NO 12
LENGTH, 18
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 12
augcucaaua ggauuacg

<210>
<211>
<212>
<213>

18

SEQ ID NO 13
LENGTH, 18
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 13
agaaauugcc caaacaau

<210>
<211>
<212>
<213>

18

SEQ ID NO 14
LENGTH, 18
TYPE, RNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 14
aaaguuuuau uuaccuau

18

us
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36
-continued

<210> SEQ ID NO 15
<211> LENGTH, 36
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

15

aguauugagc auagccgcug caauucuuau ggccaa

36

<210> SEQ ID NO 16
<211> LENGTH, 10
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

16

gcauagccgc

10

<210> SEQ ID NO 17
<211> LENGTH, 195
<212> TYPE, RNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

17

ggaucgguau guagcaauac guaauccuau ugagcauagc cguuucaauu cgcggacuaa

60

ggccaucaug aagauugcua uuguuugggc aauuucuaua gguaaauaaa acuuuuuggc

120

cauaagaauu gcagcggcua ugcucaauac uuucggauua uguacuguga acaacguaca

180

gacgucgacu gguaa

195

<210> SEQ ID NO 18
<211> LENGTH, 195
<212> TYPE, RNA
<213> ORGANISM, Macaca mulatta
<400> SEQUENCE,

18

ggaucgguau guagcaauac guaauccuau ugagcauagc cguuucaauu cgcggacuaa

60

ggccaucaug aagauugcua uuguuugggc aauuucuaua gguaaauaaa acuuuuuggc

120

cguaagaauu gcagcggcua ugcucaauac uuucggauua uguacuguga acaacguaca

180

gacgucgacu gguaa

195

<210> SEQ ID NO 19
<211> LENGTH, 195
<212> TYPE, RNA
<213> ORGANISM, Pan troglodytes
<400> SEQUENCE, 19

ggaucgguau guagcaauac guaauccuau ugagcauagc cguuucaauu cgcggacuaa

60

ggccaucaug aagauugcua uuguuugggc aauuucuaua gguaaauaaa acuuuuuggc

120

cauaagaauu gcagcggcua ugcucaauac uuucggauua uguacuguga acaacguaca

180

gacgucgacu gguaa

195

<210>
<211>
<212>
<213>

SEQ ID NO 20
LENGTH, 194
TYPE, RNA
ORGANISM, Canis familiar is

<400> SEQUENCE, 20

ggaucgguau guagcaauac guaauccuau ugagcauagc cguuucaauu cgcggacuaa

60

ggccaucaug aagauugcua uuguuugggc aauuucgaua gguaaauaac guucuuggcc

120
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37
-continued
auuagaauug cagcggcuau gcucaauacu uucggauuau guacugugaa caacguacag

180

acgucgacug guaa

194

<210> SEQ ID NO 21
<211> LENGTH, 194
<212> TYPE, RNA
<213> ORGANISM, Sus scrofa
<400> SEQUENCE,

21

ggaucgguau guagcaauac guaauccuau ugagcauagc cguuucaauu cacggacuaa

60

ggccaucaug aagauugcua uuguuugggc aauuucuuua gguaaugaac uuucuuggcc

120

aguagaauug cagcggcuau gcucaauacu uucggauuau guacugugaa caacguacag

180

acgucgacug guaa

194

<210> SEQ ID NO 22
<211> LENGTH, 194
<212> TYPE, RNA
<213> ORGANISM, Bos taurus
<400> SEQUENCE,

22

ggaucgguau guagcaauac guaauccuau ugagcauagc cguuucaauu cacggacuaa

60

ggccaucaug aagauugcua uuguuugggc aauuucuuua gguaauuaac uuucuuggcc

120

aguagaauug cagcggcuau gcucaauacu uucggauuau guacugugaa caacguacag

180

acgucgacug guaa

194

<210> SEQ ID NO 23
<211> LENGTH, 190
<212> TYPE, RNA
<213> ORGANISM, Mus musculus
<400> SEQUENCE,

23

ggaccgguau guagcaauac guaauccuau ugagcauagc cgguucaauu cgcggacuaa

60

ggccaucaug aagauugcca ucguuugggc aauaucaaua gguaauuaua ccuggccaua

120

gaauugcagc ggcuaugcuc aauaccuucg gauuauguac ugugaacaac cuacagacgu

180

cgacugguaa

190

<210>
<211>
<212>
<213>

SEQ ID NO 24
LENGTH, 190
TYPE, RNA
ORGANISM, Rattus rattus

<400> SEQUENCE, 24

ggaccgguau guagcaauac guaauccuau ugagcauagc cgguucaauu cgcggacuaa

60

ggccaucaug aagauugcca ucguuugggc aauaucaaua gguaaauaua ccuggccaua

120

gaauugcagc ggcuaugcuc aauaccuucg gauuauguac ugugaacaac cuacagacgu

180

cgacugguaa

190

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 25
LENGTH, 147
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Section of the Homo sapien pre-mRNA 5-HT2C
receptor sequence

<400> SEQUENCE, 25
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39
-continued
uacguaaucc uauugagcau agccguuuca auucgcggac uaaggccauc auagagauug

60

cuauuguuug ggcaauuucu auagguaaau aaaacuuuuu ggccauaaga auugcagcgg

120

cuaugcucaa uacuuucgga uuaugua

147

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 26
LENGTH, 195
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Section of the Homo sapien pre-mRNA 5-HT2C
receptor sequence

<400> SEQUENCE, 26
ggaucgguau guagcaauac guaauccuau ugagcauagc cguuucaauu cgcggacuaa

60

ggccaucaug aagauugcua uuguuugggc aauuucuaua gguaaauaaa acuuuuuggc

120

cauaagaauu gcagcggcua ugcucaauac uuucggauua uguacuguga acaacguaca

180

gacgucgacu gguaa

195

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 27
LENGTH, 45
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Sequence product for the Vb splice site
following control treatment

<400> SEQUENCE, 27
gaccggtatg tagcagtgcg taatcctgtt gagcatagcc ggttc

<210>
<211>
<212>
<213>
<220>
<223>

45

SEQ ID NO 28
LENGTH, 45
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Sequence product for the Vb splice junction
following treatment with oligo 5

<400> SEQUENCE, 28
gaccggtatg tagcagtgcg taatcctgtt gagcatagcc ggttc

45
45

What is claimed is:
1. A method of modulating human 5'-HT2C receptor

(HTR2C) activity in a cell, the method comprising delivering to the cell an anti sense oligonucleotide of 10-50 nucleotides in length comprising a sequence that permits specific
hybridization to a target region of a human 5'-HT2C receptor
(HTR2C) pre-mRNA under stringent conditions, wherein
the target region comprises a nucleotide sequence 5' UUGGCCAUAAGAAUUGCAGCGGCUAUGCUCAAUACU
3' (SEQ ID NO: 1) and;

50
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the antisense oligonucleotide comprises a sequence at
least 95% identical to 18 or more contiguous nucleotides that appear in:
60

4. The method of claim 1, wherein the antisense oligonucleotide is 5' AGUAUUGAGCAUAGCCGC 3' (SEQ ID
NO: 5).
5. The method of claim 4, wherein the antisense oligonucleotide is administered at a concentration greater than 5
nM.
6. The method of claim 1, wherein the stringent conditions
comprise 50% formamide with 1 mg heparin at 42° C. with
hybridization carried out overnight and a wash in 0.2xSSC
at 65° C. for 15 minutes.
7. The method of claim 1, wherein the sequence permits
specific hybridization to nucleotides 1-18 of SEQ ID NO: 1.
8. The method of claim 1, wherein the sequence permits
specific hybridization to nucleotides 10-27 of SEQ ID NO:

1.
9. The method of claim 1, wherein the sequence permits
specific hybridization to nucleotides 19-36 of SEQ ID NO:

(SEQ ID NO, 15)
5' AGUAUUGAGCAUAGCCGCUGCAAUUCUUAUGGCCAA 3'.

2. The method of claim 1, wherein the cell is a neuron.
3. The method of claim 2, wherein the neuron is in the

hypothalamus region of the brain.

1.
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10. The method of claim 1, wherein the sequence permits
specific hybridization to nucleotides 19-30 of SEQ
ID NO: 1.
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11. The method of claim 1, wherein the antisense oligo-

nucleotide comprises a sequence selected from the group
consisting of 5' UGCAAUUCUUAUGGCCAA 3' (SEQ ID
N0:8), 5' CAUAGCCGCUGCAAUUCU 3' (SEQ ID
N0:4), or 5' AGUAUUGAGCAUAGCCGC 3' (SEQ ID s
N0:5), and combination thereof.

* * * * *
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